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ABSTRACT
Williams, Jesica R. Ph.D. The University of Memphis. August 2012. Molecular
Modeling and Experimental Studies on Ligand Recognition in the LPA5 G ProteinCoupled Receptor. Major Professor: Abby L. Parrill, Ph.D.
Lysophosphatidic acid (LPA) is a phospholipid growth factor mediating numerous
biological effects such as platelet aggregation, mast cell activation, cell differentiation,
cell migration, and cell survival by acting on specific LPA G protein-coupled receptors.
Currently there are nine LPA receptors identified in the literature, LPA1-9. LPA1-3 are
members of the endothelial differentiation gene (EDG) family and share approximately
50% sequence identity at the primary sequence level. LPA4-9 are structurally distinct
from the EDG receptors with LPA5 sharing approximately 30% sequence identity with
LPA4 at the primary sequence level. Due to the emerging role of LPA5 in human platelet
activation, cancer, and neuropathic pain, a thorough characterization of LPA5 is needed
for the development of compounds to serve as starting points for anti-thrombotic and
anti-cancer therapies as well as to inhibit neuropathic pain. In this dissertation we
describe LPA5 pharmacophore model development and performance, LPA5 homology
model evaluation and optimization through site-directed mutagenesis studies, and
structure-activity relationships (SAR) analysis at LPA5. Docking simulations were
performed with the LPA5 homology model to computationally identify residues involved
in ligand recognition. Pharmacophore modeling was performed to identify compounds
with functional groups necessary for receptor inhibition to serve as starting points for
therapeutic lead discovery.

Our pharmacophore models identified weak partial

antagonists and we validated headgroup recognition in alkyl-LPA (AGP 18:1),
octadecenylthiophosphate (OTP 18:1), and oleyl-LPA (LPA 18:1).
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Specifically we

proved three cationic residues to be involved in headgroup recognition: R78 (R2.60),
R261 (R6.62), and R276 (R7.32). Furthermore we confirmed F71 (F2.53), F101 (F3.32),
and M105 (M3.36) as three important residues involved in hydrophobic interactions with
the AGP, OTP, and LPA ligands. Also, we confirmed an alkyl-LPA preference in LPA5
relative to acyl-LPA. The SAR results suggests that the LPA5 binding pocket exhibits a
bend that better accomadates cis relative to trans alkenes located 9 carbons from the
headgroup, and that surrounding regions of the binding pocket are less bent, disfavoring
recognition of ligands with cis double bonds located closer to or farther from the
headgroup.
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PREFACE
This Ph.D. dissertation consists of five chapters. Chapter 1 gives an introduction
to G protein-coupled receptor structure and function, LPA receptors and LPA receptor
signaling, the biomedical relevance of LPA5, and molecular modeling techniques utilized
in therapeutic lead discovery. Chapter 2 highlights structure-based and ligand-based
pharmacophore model development and the performance of the antagonist ligand-based
pharmacophore in therapeutic lead discovery. Chapter 3 describes our efforts in
homology model development and model validation through docking and site-directed
mutagenesis studies. Chapter 4 describes the structure-activity relationship (SAR)
analysis of LPA5 based on known ligands, and based on new assays of fatty alcohol
phosphates (FAP) and fatty acids. Chapter 5 concludes the findings of the work on LPA5
and integrates both computational and experimental studies to explain the shape and
charge of the agonist binding pocket.
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INTRODUCTION
G Protein-Coupled Receptor Structure and Function
G protein-coupled receptors (GPCR) are signaling molecules embedded in a lipid
bilayer that couple to heterotrimeric guanine nucleotide binding proteins, or G-proteins,
upon ligand activation (1). Characteristic features of GPCR include seven alpha helical
transmembrane (TM) domains spanning the cell plasma membrane, in addition to an
extracellular amino terminus and three extracellular loops as well as an intracellular
carboxyl terminus and three intracellular loops (Figure 1). GPCR mediate
communication between the cell and its local environment by transducing an external
signal into an internal response and are responsible for vision, olfaction, and taste (2).
Cellular responses produced by GPCR upon ligand recognition include cellular
differentiation, proliferation, migration, and survival (1, 2, 3, 4, 5). Examples of small
molecule extracellular effectors acting on GPCR to produce a desired effect include
hormones (2), odorants (6, 7), photons (8), and lipids (3, 5, 9, 10).

Figure 1. A 7TM GPCR (purple) embeddded in a lipid bilayer (yellow)
and coupled to intracellular G-proteins (magenta).
!
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G protein-coupled receptors (GPCR) are therapeutic targets for a variety of
diseases such as cardiovascular diseases (11, 12), asthma (13), and cancer (5, 14). Betaadrenoceptor ligands, antihistamines, and anti-platelet agents target the human beta-2
adrenergic receptor, the histamine H1 receptor, and the purinergic P2Y12 receptor,
respectively. More specifically the beta-adrenergic receptor agonist Salbutamol (13),
also known as Ventolin, is prescribed to treat asthma. The antihistamine
diphenhydramine (15), or Benadryl, is an over-the-counter medication to treat allergies.
The antiplatelet agent clopidogrel (12) is prescribed to treat blood clots. Due to the
evident biomedical relevance of GPCR, structures of these 7TM receptors are sought for
advances in rational-ligand design. Rational-ligand design, or structure-based drug
design, is a suite of molecular modeling techniques that benefit from the structures of
biological targets for novel therapeutic lead discovery.
GPCR crystal structures are desired by pharmaceutical researchers for optimal
design of ligands that will interact with GPCR drug targets to activate or suppress
specific biological responses. However difficulties in GPCR crystallography commonly
arise because integral membrane proteins are not soluble in detergents suitable for
crystallography and tend to be more stable in non-ionic detergents, which form larger
micelles that prevent the formation of crystal contacts (1). Additionally a high degree of
conformational flexibility (16), particularly in the loop regions, make GPCR prone to
denaturing or unfolding in solution. However designer peptide detergents have proven
successful in analysis of olfactory receptors (17); and overall progress has been made in
the structural biology field in obtaining three-dimensional diffraction crystals for select
GPCR (18, 19, 20, 21).
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Rhodopsin-Class A GPCR
More than 800 unique GPCR exist in the human genome (1, 2) and are grouped
into different classes based on sequence and structural similarity (2). GPCR in
vertebrates may be divided into the following classes: Rhodopsin (Class A), Glutamate,
Adhesion, Frizzled/Taste, and Secretin (1, 2). The rhodopsin receptors represent the
largest class of GPCR and the only class of receptors which researchers have obtained xray crystallographic data of the seven transmembrane domains (18, 19). Class A GPCR
possess structural diversity in the extracellular loop regions, however are more conserved
in the transmembrane domains. Characteristic features of Class A GPCR include the
conserved D(E)RY motif in TM3 and the conserved N(P)XXY motif in TM7 towards the
intracellular domain that participate in conformational changes associated with ligand
activation. The proline residue causes a kink or distortion in the helix, however ordered
water molecules compensate for the distortion in TM7 by hydrogen bonding with polar
sidechains (2). The ordered water molecules stabilize the inactive state and the breaking
of these solvent-mediated interactions occurs during activation by agonist binding (2).
Amino acids in the transmembrane (TM) domains were assigned index positions
to facilitate comparison between GPCR with different numbers of amino acids, as
described by Ballesteros and Weinstein (22). An index position is in the format X.YY. X
denotes the TM domain in which the residue appears. YY indicates the position of that
residue relative to the most highly conserved residue in that TM domain (Table 2), which
is arbitrarily assigned position 50. This index numbering system will be used to describe
amino acid positions in GPCR throughout this dissertation. Researchers in structurebased drug design have modeled GPCR transmembrane domains based on Class A
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crystal structure templates (20, 23), frequently using the conserved residue positions in
Table 1 as tools to verify that a quality alignment between the target sequence and the
crystal structure has been produced prior to model development. Select available Class A
GPCR crystal structures are described in Table 2.

Table 1. Conserved residues within each transmembrane domain of the human
LPA5 sequence.
Transmembrane (TM) Domain
Conserved Residue
TM1

Asparagine (N40)

TM2

Aspartate (D68)

TM3

Arginine (R119)

TM4

Tryptophan (W146)

TM5

Proline (203)

TM6

Proline (249)

TM7

Proline (294)
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Table 2. Select Class A GPCR crystal structures.
PDB
Crystal Structure

Length

3PBL (24)

Human dopamine D3 receptor an D2/D3 antagonist complex

481aa

3V2W (25)

Human S1P1 receptor with antagonist ML056

520aa

3RZE (26)

Human histamine H1 receptor and doxepin complex

452aa

4DKL (27)

µ-opioid receptor and morphinan antagonist complex

464aa

4DJH (28)

Human kappa opioid receptor and JDTic complex

480aa

4DAJ (29)

M3 muscarinic acetylcholine receptor

479aa

3UON (30)

467aa

3EML (31)

Human M2 muscarinic acetylcholine receptor and antagonist
complex
Human A2a adenosine receptor and antagonist complex

3ODU (32)

CXCR4 chemokine GPCR and antagonists complex

502aa

2RH1 (33)

Human beta-2 adrenergic G protein-coupled receptor

500aa

2VT4 (34)

Beta-1 adrenergic G protein-coupled receptor

315aa

1F88 (35)

Rhodopsin and retinal complex

348aa

488aa

Ligand binding generally occurs within the transmembrane domains or
extracellular loops of Class A GPCR (19). Although the transmembrane domains possess
sequence similarity and conserved motifs, structural diversity is found in the extracellular
loops. In particular, extracellular loop 2 (ECL2) of the Rhodopsin, Kappa Opioid, Mu
Opioid, and CXCR4 chemokine receptor crystal structures (27, 28, 32, 35) is a betastrand that covers the ligand binding pocket, whereas ECL2 of the beta-adrenergic
receptors is a short alpha helical segment that keeps the pocket open for ligand binding.
The D2/D3, histamine H1, adenosine, S1P1, and muscarinic receptors lack secondary
structures in ECL2 (24, 26, 26, 29, 30).
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G-Protein Signal Transduction
G protein-coupled receptors are known to exist in both active and inactive
conformational states (1, 2). The active state of the receptor, R*, is stabilized by agonist
(activating ligand) binding (1, 2). A full agonist completely activates the receptor
producing a 100% biological response and causes a conformational change in the
receptor facilitating G-protein coupling (2). A partial agonist activates the receptor as
well, albeit with sub maximal activity (2). The inactive state of the receptor, R, is
stabilized by an inverse agonist, which inhibits basal activity of the receptor (2). A
neutral antagonist does not have a preference for a conformational state, does not affect
the basal equilibrium of the receptor, and blocks agonist binding consequently inhibiting
agonist-induced receptor activity (2).
Upon ligand activation, a conformational change occurs within the receptor
facilitating G-protein activation of intracellular signaling (3, 36). Heterotrimeric guanine
nucleotide binding proteins, G-proteins, are a family of proteins involved in intracellular
signaling. The proteins contain alpha (!), beta ("), and gamma (#) subunits, and although
both ! and " subunits have the ability to regulate specific effector molecules, G-proteins
are commonly referred to by their ! subunits (36). Following guanosine diphosphate
(GDP) exchange for guanosine triphosphate (GTP), the ! subunit dissociates from the
intact "# subunit and downstream signal transduction occurs inside the cell in a G!
subtype-dependent manner (Figure 2). The G!s, or G-stimulatory protein, stimulates the
effector molecule adenylyl cyclase, which increases intracellular cyclic adenosine
monophosphate (cAMP) levels (3). The second messenger cAMP activates the
phosphorylating agent protein kinase A (PKA), which modulates the long-lasting
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activation (L)-Type calcium channel (2). The G!i, or G –inhibitory protein, inhibits
adenylyl cyclase activity (2). G!q activates phospholipase C, which cleaves
phosphoinositide bisphosphate (PIP2) into inositol-trisphosphate (IP3) and diacylglycerol
(DAG) (3). IP3 signals result in an increase in intracellular calcium (Ca2+) and DAG
activates the phosphorylating agent protein kinase C (PKC) (3). G!12/13 activates Rho, a
GTPase, and Rho activates the Rho-associated protein kinase (ROCK) (3) which initiates
actin organization and cell migration (37). Rho also signals to the serum response factor
(SRF) (3), a transcription factor responsible for gene expression. GTP is hydrolyzed
back to GDP by the regulator of G-protein signaling (RGS). RGS are GTPase-activating
proteins (GAPs) for G! subunits (38). After hydrolysis of GTP to GDP, the ! and "#
subunits reassociate forming the original heterotrimer, and the activation cycle is
terminated (36). Receptor level signaling is shown in Figure 2.
Following prolonged exposure of receptor to ligand, the receptor may internalize.
The process of receptor internalization, or receptor desensitization, involves
phosphorylation of serine and threonine residues by protein kinases or G protein receptor
kinases (GRK) on the intracellular domain of the receptor (2). The regulatory protein
beta-arrestin then binds to the phosphorylated sites and the receptor internalizes through
clathrin-mediated endocytosis (2). In the beta-2 adrenergic system, GRK promotes betaarrestin binding thus preventing receptor association with G-protein. Second messenger
kinase regulation by PKA or PKC also prevents receptors from interacting with their
respective G-proteins. The internalized receptor can either go on to G-protein
independent signaling through the extracellular regulated kinase (ERK) and mitogenactivated kinase (MAPK) pathways leading to gene expression, or the receptor may be
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targeted to lysosomes for degradation (2). Also, the receptor may return back to the cell
surface to participate in further ligand-dependent signaling. Essentially receptor
desensitization occurs when the receptor has been continuously exposed to agonist
resulting in lowered receptor response to agonist and reduced signaling. Figure 3 shows
a schematic of beta-2 adrenergic receptor internalization.

Figure 2. A GPCR in the active conformation and G-protein downstream
signaling pathways.
!
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Figure 3. Human beta-2 adrenergic receptor internalization. Receptor (blue) with bound
agonist (cyan) is internalized after beta arrestin (green) binding to phosphorylated sites by
GRK (magenta) or PKC (purple) on receptor's intracellular domain.
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Lysophosphatidic Acid
Lysophosphatidic acid (LPA) [1-acyl-sn-2-hydroxyl-3-phosphate] is an
extracellular signaling molecule that mediates a variety of cellular responses by acting on
specific GPCR (3, 4, 10). The structurally simple glycerol phospholipid (Figure 4)
consists of a phosphate group, a three carbon glycerol group, and an ester linker to a
hydrocarbon chain. Various species of LPA exist differing based on chain length or
degree of unsaturation; however LPA 18:1, shown in Figure 4, is one of the more
common forms of LPA used as a laboratory reagent.

Figure 4. Lysophosphatidic acid (LPA 18:1)

LPA biosynthesis is predominately mediated by the enzyme autotaxin (5).
Autotaxin, or ectonucleotide pyrophosphatase/phosphodiesterase family member 2
(ENPP2), was initially recognized as an autocrine motility factor for melanoma cells and
is involved in tumor progression (5). Autotaxin exhibits lysophospholipase D activity
using lysophospatidylcholine as a substrate, producing LPA (Figure 5). LPA then acts on
LPA receptors (3, 10, 39) causing G protein activation of downstream signaling. Aside
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from the lysophospholipase D activity of autotaxin on LPC, the mild oxidation of
lipoproteins is also a source of LPA production (40). LPA is present at low
concentrations in eukaryotic tissues and higher concentrations in blood plasma (3). LPA
plasma concentration is in the high nanomolar range and LPA serum concentration is in
the micromolar range (3).

Figure 5. Bioconversion of lysophosphatidylcholine (LPC) to lysophosphatidic acid
(LPA) by autotaxin.

LPA is a bioactive phospholipid documented to play a role in atherosclerosis (11,
40, 41) and in various cancers (5, 14). LPA is generated by activated platelets, present in
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mildly oxidized low-density lipoprotein, and atherosclerotic plaques (40, 41). Oxidized
lipoproteins and platelet activation are precursors to atherosclerosis. Lipid rich
atherosclerotic plaques rupture, the lipid-rich core is exposed and can activate platelets
circulating in the blood. This causes thrombus formation and can lead to ischemic stroke
or myocardial infarction (40). The G!12/13 and G!i signal transduction pathways are
activated during platelet shape change leading to cardiovascular diseases. Low
concentrations of LPA and mildly oxidized low-density lipoprotein can activate platelet
shape change initiated by signaling through the G!12/13 mediated Rho and Rho Kinase
pathway and the G!i mediated activation of the Src family of tyrosine kinases (41). The
former pathway leads to actin cytoskeletal changes, whereas the latter pathway leads to
exposure of the fibrinogen binding sites on the integrin !IIb"3, which is a precursor for
platelet aggregation (40). Higher concentrations of LPA are required to increase
cytosolic Ca2+ in platelets. However the increase in Ca2+ is caused by an influx of Ca2+
from the extracellular space and not intracellular Ca2+ mobilization because LPA does not
activate PLC in human platelets (40). Aside from cardiovascular diseases, LPA is also
involved in cancers of the ovaries, prostate, thyroid, and breasts amongst other cancers
(5). The primary evidence of LPA involvement in cancer came from studies that showed
LPA to increase motility and invasiveness of cells (5, 42).
Lysophosphatidic Acid Receptor Family
LPA is an extracellular signaling molecule that acts on specific GPCR to produce
diverse cellular responses and biological effects. Cellular responses mediated by LPA
signaling include cellular differentiation, proliferation, migration, survival, actin
cytoskeleton organization (3, 4, 5), smooth muscle contraction and platelet aggregation
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(40) via acting on specific cell surface GPCR. Biological actions of LPA receptors also
include wound healing and tumor invasion (5). Presently there are reports of nine LPAGPCR in the literature, six confirmed and three putative (3, 43, 44, 45). These receptors
differ based on expression patterns and G-protein downstream signaling. Of the nine
unique GPCR with LPA as an endogenous ligand, LPA1-3 are the more thoroughly
characterized LPA receptors in the literature.
Endothelial Differentiation Gene Family
The most thoroughly studied LPA receptors are members of the EDG family. The
first LPA receptor to be deorphanized, EDG-2/LPA1, was identified in 1996 (3, 46).
LPA1 consists of 364aa, couples to G!q, G!12/13, and G!i, and has functions in cortical
neurogenesis (46). LPA2 is a 348aa protein that has a 60% amino acid similarity to LPA1
and also couples to G!q, G!12/13, and G!i (3, 47). The physiological roles of LPA2 have
been documented in cell survival (48), cell migration (49) and cancer (50). LPA2
activation leads to cell survival and migration, which play a role in cancer metastasis.
LPA3 shares approximately 50% identity with LPA1 and LPA2 amino acid sequences and
couples to G!i and G!q (3). Therefore LPA3 does not mediate cell rounding in neuronal
cells through G!12/13 coupling (3). While LPA1 and LPA2 have broad expression patterns
in multiple tissues (3), the expression of LPA3 is more restricted to the heart, testis,
prostate, and pancreas (51).
Non-Endothelial Differentiation Gene Family
LPAR4/p2y9/GPR23 (52, 53) LPA5/GPR92/GPR93 (54, 55), LPA6/p2Y5 (56),
LPA7/GPR87 (43), LPA8/p2Y10 (44), and LPA9/GPR35 (45) are structurally distinct
from the classic EDG receptors at the primary sequence level and are grouped into the
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non-EDG family of LPA receptors (LPA4-9) (39). LPA4 and LPA5 are the more
thoroughly characterized receptors from this second cluster of LPA receptors (3). LPA4
is expressed primarily in the ovaries (3) while LPA5 has broader expression in the spleen,
placenta, small intestine, lymphocytes, and heart (3, 54, 55). A phylogenetic analysis
representative of the sequence identities between LPA receptor sequences is provided in
Figure 6.

Figure 6. LPA receptor phylogenetic analysis.
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LPA5 Receptor Biomedical Relevance
LPA5 is a 372aa protein that researchers have not yet crystallized however is a
relatively well characterized non-EDG LPAR. In 2006 two independent research groups
published data on LPA5 as a novel LPA receptor (54, 55). Kotarsky and colleagues
found LPA contained in serum to activate LPA5 in a concentration dependent and
specific manner (54). Lee and colleagues screened collections of GPCR cDNA for an
additional LPA receptor and found LPA5 to signal through Gq and G12/13 proteins and to
increase intracellular cAMP levels independent of Gs (55). LPA5 raises intracellular
cAMP levels, although independent of the Gs pathway (55). Jongsma et al recently
confirmed that LPA-induced chemorepulsion is mediated by the alkyl-LPA preferring
receptor LPA5 and proved LPA5 as an anti-migratory receptor (57). Lin et al has also
confirmed through partial sciatic nerve ligation that LPA mediates neuropathic pain by
signaling through LPA5 (58).
LPA5 is a potential mediator of platelet activation and human mast cell activation.
LPA5 is one of the most abundant LPA receptors expressed in human platelets at the
mRNA level (59, 60, 61). Platelets or thrombocytes are small anuclear cells, produced
from the fragmentation of megakaryocytes. Platelets circulate in the blood and can lead
to thrombus formation upon activation (60). Khandoga and colleagues used silencing
RNA to knock down individual LPAR and confirmed LPA5 to be the dominant LPA
receptor involved in human platelet activation (59). Lundequist and Boyce proved LPA5
to be the dominant LPA receptor expressed on human mast cells at the mRNA level (62).
Mast cells are involved in allergy, inflammation, immunity, and cancers (63). From the
knockdown of individual LPAR using short hairpin RNA, Lundequist and Boyce
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demonstrated LPA5 to mediate LPA-induced calcium flux and suggested LPA5 may
mediate a pathway for mast cell activation in cases where cancers result in the production
of LPA (62). Compounds that inhibit LPA-induced platelet activation might serve as a
starting point for antithrombotic therapies, whereas compounds used to probe possible
signaling pathways of LPA5 in cancer might serve as a starting point for cancer therapy.
Due to the lack of three-dimensional structural information on the LPA5 target
receptor, we have utilized molecular modeling techniques investigate ligand recognition
in LPA5. Specifically we introduced site-specific mutations into the LPA5 sequence and
monitored LPA recognition through intracellular calcium mobilization in response to
LPA. Site-directed mutagenesis was performed to identify residues involved in ligand
LPA phosphate group recognition (64). Several mutants were made using either the
polymerase chain reaction (PCR) overlap extension method or the QuikChangeII
mutagenesis kit. The mutants were then tested on known agonists to monitor changes in
ligand recognition relative to wildtype. We determined amino acid residues involved in
LPA phosphate head group recognition within LPA5 to be R78 (R2.60), H160 (H4.64),
R261 (R6.62), and R276 (R7.32) (64). Our molecular modeling results suggest the
phosphate group of LPA to have critical electrostatic interaction with these three cationic
arginine residues as well as a possible hydrogen bonding interaction between the
hydroxyl group of the glycerol backbone of LPA and the neutral histidine residue at
position 160. Experimental site-directed mutagenesis coupled with computational
simulations such as homology modeling, docking, and molecular dynamics is discussed
more extensively in Chapter 3 of this dissertation.
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Molecular Modeling
Molecular modeling is a computational technique often utilized for modeling
macromolecules to predict and explain experimental results. While quantum mechanical
calculations accurately describe electrons within smaller systems, many of the systems
studied in molecular modeling contain numerous atoms and are too large to be considered
by quantum mechanics (65). Molecular mechanics disregards electronic motions and
uses forcefields to describe nuclei position. It saves computational time and resources,
and is appropriate for the study of biological targets or macromolecules with numerous
atoms. Molecular modeling using molecular mechanics and experimental studies have
been utilized in concert to thoroughly investigate systems with numerous atom types.
Molecular Mechanics
Molecular mechanics uses forcefields to describe the energy of a system. A
forcefield is a set of equations and parameters describing each energy contribution to the
system of study at a moment in time. Molecular mechanics relies on the BornOppenheimer approximation to study the energy of a system as a function of nuclear
position (Equation 1) by disregarding electronic motion (65). Molecular modeling
forcefields generally describe both intramolecular and intermolecular forces within a
system (65). Equation 2a displays a generalized forcefield equation, which encompasses
bonding, non-bonding, angle, and dihedral angle energy terms. Equation 2b displays the
equation for the energy of the non-bonding term including electrostatic and van der
Waals terms.
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E = f(nuclei position)

(Equation 1)

E = Ebonds + Enonbonded + Eangle + Edihedral

(Equation 2a)

Enonbonded = Eelectrostatics + Evan der Waals

(Equation 2b)

Several forcefields exist for modeling protein systems such as CHARMM (66,
67), OPLS (68, 69), GROMOS (70), AMBER (71, 72), and MMFF94 (73). The Assisted
Model Building and Energy Refinement (AMBER) forcefield has been utilized to obtain
accurate protein backbone dihedral angles (71). The optimized potentials for liquid
simulations (OPLS) forcefield is primarily used for the simulation of proteins in solution
or crystalline environments (69). The chemistry at Harvard macromolecular mechanics
(CHARMM) forcefield has a lipid parameter that treats a variety of phospholipids (67).
The Groningen molecular simulations (GROMOS) forcefield is widely used in molecular
dynamic (MD) simulations and has been optimized to reproduce the experimental
enthalpies of vaporization or densities of alkanes (70). The Merck Molecular Force Field
(MMFF94) is used for the geometry optimization of small organic molecules (73). We
have utilized the AMBER and CHARMM forcefields for the geometry optimization of
our modeled protein-ligand interactions. The AMBER forcefield was selected for protein
modeling based on its protein backbone dihedral parameter (71) and the CHARMM
forcefield was selected for the geometry optimization of the modeled protein-lipid
complexes based on its lipid parameter (67). Molecular systems have both global and
local minima on their potential energy surfaces. Geometry optimization of a molecular
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system produces in a local minimum of potential energy downhill from the starting
configuration.
Molecular dynamics is used to study the behavior of a system undergoing
vibrational motion over a period of time. Newton’s laws of motion are applied to
generate multiple configurations of a system (65, 74). The process of molecular
dynamics involves applying kinetic energy to the system of study and investigating how
the atoms in the system adapt to changes in configuration brought about the kinetic
energy. Molecular dynamics simulations can be used to mimic conformational changes
of biomolecules by generating a trajectory that specifies how atomic position and velocity
changes with time (65).
Pharmacophore Modeling
Pharmacophore modeling is a computational simulation utilized in virtual
screening for the identification of novel leads. A pharmacophore is a three-dimensional
spatial arrangement of functional groups predicted to interact with a target molecule to
elicit a biological response (75). Two types of pharmacophore modeling are utilized in
virtual screening: structure-based and ligand-based pharmacophore modeling. A
structure-based pharmacophore can be developed from the docked superposition of active
compounds (75); and the ligand-based pharmacophore is developed from a flexible
alignment of active compounds (75). Both types of pharmacophore modeling have been
utilized in drug discovery (75).
A structure-based pharmacophore can be developed from dockings into crystal
structures or homology models. Pharmacophore points essential for biological activity
are then defined by the overlay of functional groups within structures of the docked
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ligands and observed interactions with the docked protein. Databases are screened
against the structure-based pharmacophore to identify novel compounds matching the
molecular features and dimensions of the pharmacophore.
A ligand-based pharmacophore can be used to identify novel leads when there is
no structural information available on the biological target. An assumption of ligandbased pharmacophore modeling is that ligands with similar activity will flexibly align
well exhibiting a superposition that places similar functionality in a common threedimensional space. Pharmacophore points are defined by the overlay of functional
groups from the flexible alignment. Databases are then screened against the ligand-based
pharmacophore for compounds matching the shape and dimensions of the
pharmacophore. Our efforts in structure-based and ligand-based pharmacophore
modeling are discussed more extensively in Chapter 2 of this dissertation.
Protein Modeling
GPCR possess important physiological functions and structures of these
biomolecular targets are desired by pharmaceutical researchers for the design and
optimization of therapeutic leads. Researchers dock into crystal structures and homology
models to study and predict protein-ligand binding conformations (23). Protein-ligand
interactions predicted necessary for biological activity are studied using molecular
modeling. Homology modeling in combination with experimental studies has provided
structural insights on drug action at GPCR (23, 76).
Comparative/Homology Modeling
Homology modeling of protein targets, also referred to as comparative modeling,
is a method of computation used to model proteins of which there is no atomic-resolution

!

#+!

three-dimensional crystal structure (77). Although advances have been made in x-ray
crystallography and structural characterization studies for obtaining GPCR crystal
structures, many GPCR presently lack crystal structures. Thus three-dimensional
homology models serve as an effective interim source of structural information for use in
structure-based drug design. A homology model is developed by modeling a target of
unknown structure based on a homologous crystal structure template (77) with
homologous function. The homology modeling process consists of aligning the target
sequence to the template sequence, constructing the homology model, and validating the
model for use in virtual screening. Common model validation techniques include using
experimental site-directed mutagenesis and structure-activity-relationship studies.
Validated homology models can be applied in structure-based drug design for the
identification of novel therapeutic leads.
Homology models of protein targets are used in structure-based drug design for
the identification of novel leads with chemical diversity. In our studies we developed a
homology model of LPA5 (64) based on a potentially validated LPA1 receptor model
template (9, 78, 79). We selected the LPA1 receptor model as a template because none of
the crystal structure templates available at the time of preliminary homology model
development possessed a higher degree of sequence similarity to LPA5. Furthermore,
LPA phosphate group interactions within LPA1 were previously validated in site-directed
mutagenesis studies (9). The validated LPA1 receptor model possessed predictive power
and was therefore selected as the template for homology modeling of LPA5. The
homology model has been optimized through a combination of computational and
experimental techniques. The computational techniques employed in homology model
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optimization of LPA5 include molecular docking and molecular dynamics. The
optimization of the previously published homology model is described more extensively
in Chapter 3 of this dissertation.
Docking
Automated docking is a computational simulation used to predict small molecule
binding at a biological target. Docking is commonly used in structure-based drug design
to predict bioactive conformations of known ligands and to computationally identify
novel chemically-diverse leads (80). A three-dimensional crystal structure or homology
model is required for docking simulations to study known ligand interactions with protein
targets or to predict ligand activity. An assumption of structure-based drug design is that
activators or inhibitors must be structurally and chemically complementary to the binding
pocket of the target (81). Candidate leads that possess similar interactions and bind in a
common mode as known actives are predicted to be active. Thus docking is a
computational technique that can be used to screen databases for novel therapeutic leads
by assessing and scoring candidate drug compounds (82).
Docking simulations predict both binding conformations and binding energies,
however perform better in identifying ligand geometry (81, 83). In our studies we
utilized AutoDock 4.0 (84) for modeling protein-ligand interactions within the LPA5
system. Automated docking involves a thorough sampling of the ligand’s conformational
space, however there is a need to keep computational demands at a reasonable level.
Docking ligands rigidly enhances the computational speed of the simulation as torsional
degrees of freedom are disregarded, relative to the flexible docking of ligands. Protein
mobility upon ligand binding may also be modeled by allowing protein flexibility in
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select sidechains. For our studies we have flexibly docked all ligands into a rigid LPA5
receptor model. Homology modeling and docking is discussed more extensively in
Chapter 3 of this dissertation.
LPA5 Research Overview
This dissertation describes an investigation of structural features necessary for
ligand recognition in LPA5. Site-directed mutagenesis was performed to identify residues
involved in ligand recognition and to validate the LPA5 homology model. Docking
simulations with the LPA5 homology model was used as a guide to select residues to
mutate for the investigation of residues involved in ligand recognition. We used
molecular dynamics simulations to relax the modeled protein-ligand systems and to
monitor changes in the systems brought about kinetic energy over time. Furthermore we
expanded the structure-activity relationship (SAR) of LPA5 by screening several fatty
alcohol phosphates (FAP) and fatty acids for agonism to investigate preferred headgroup,
chain length, and double bond position necessary for optimal receptor activity.
Homology model development, docking, and model validation through site-directed
mutagenesis studies is described in Chapter 3 of this dissertation. Agonist LPA SAR
studies are discussed in Chapter 4 of this dissertation. The conclusions presented in
Chapter 5 integrates both computational and experimental results obtained through
homology modeling and docking, molecular dynamics, site-directed mutagenesis, and
SAR studies to explain the shape and charge of the LPA5 agonist binding pocket as well
as to provide a possible explanation for the alkyl-LPA preference in LPA5 relative to
acyl-LPA. Finally the computational and experimental results were integrated to suggest
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a novel, candidate LPA5 agonist that would activate the receptor by stabilizing the agonist
binding pocket and be used in future studies to further expand the SAR of LPA5.
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LPA5 ANTAGONIST PHARMACOPHORE MODELING
In computer-aided drug design (CADD) pharmacophore modeling is a commonly
used method for the identification of promising drug candidates for experimental
screening (75). A pharmacophore is a three-dimensional spatial arrangement of a set of
features common to known actives that confer the shared biological activity (65). The
pharmacophore features, or functional groups within structures of known ligands, are
those hypothesized to interact with a target molecule to elicit a biological response. The
spatial arrangement of pharmacophore features can be expressed as a set of distance
ranges, angles, or planes (65). Geometric features defining a pharmacophore might
include hydrogen bond donors, hydrogen bond acceptors, cationic, anionic, or
hydrophobic and aromatic features. Restriction on shape can also be applied through
volume exclusion feature points. Pharmacophore modeling has allowed researchers to
identify drug-target interactions necessary for biological activity, and has also provided
enrichment of experimental screening hit rates obtained from in silico virtual screening
(65 pgs.648-658).
We utilized both structure-based and ligand-based pharmacophore modeling to
identify novel LPA5 antagonists. Specifically the preliminary LPA5 homology model
previously published (64) and described in Chapter 3 was used in structure-based
antagonist pharmacophore model development. However in addition to the structurebased pharmacophore developed from the docked superpositions of known agonists, we
developed an antagonist ligand-based pharmacophore based on the flexible alignment of
known antagonists. The Pharmacophore Elucidator in the Molecular Operating
Environment (MOE) (85) generated multiple ligand-based pharmacophore queries based
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on an input database of known active and inactive compounds. The input database or
training set of active and inactive compounds is shown in Table 3. A test set of
compounds, shown in Table 4, was used to evaluate the relative merits of the
pharmacophore queries. From the test set evaluation, we selected ligand-based
pharmacophore queries different in geometry and features from the structure-based
pharmacophores, for use in conformational database screening for the identification of
novel ligands for experimental assay. Because we had validated only LPA phosphate
group recognition within our homology model of LPA5 (64) at the time the antagonist
structure-based pharmacophore was developed we did not use the structure-based
pharmacophore for virtual screening. Also in the absence of crystal structures, ligandbased models generated from the flexible alignment of known ligands have been utilized
in lead discovery (65, 75). Furthermore, ligand-based pharmacophore modeling relies
on the assumption that flexible alignments identify the shared shapes that can exhibit
common interactions necessary for biological activity. Therefore the ligand-based
pharmacophores developed from the flexible alignment of known actives were utilized in
our virtual screening efforts.
Structure-Based Pharmacophore
A structure-based pharmacophore is defined by interactions observed in the drugtarget complex. The overlay of common functional groups from a superposition of the
complexes of known actives defines structure-based pharmacophore points responsible
for biological activity. Docking simulations are often performed to generate the drugtarget complexes necessary to determine the drug-target interactions necessary for
biological activity. In general weak, non-covalent, reversible interactions are involved in

!

#'!

the drug-target complex. Common interactions observed between the drug and target
include ionic or electrostatic interactions, ion-dipole and dipole-dipole interactions,
hydrogen bonding interactions, !- ! and cation- ! stacking interactions, and hydrophobic
interactions (86 pgs.123-130). Ionic or electrostatic interactions between oppositely
charged atoms in the drug and target can provide a standard binding free energy
contribution of -5 kcal/mol$Å. Ion-dipole interactions between ions and water can
provide between -1 and -7 kcal/mol$Å. The strength of hydrogen bonding interactions
between a carbonyl oxygen and a hydroxyl hydrogen or amine hydrogen is typically in
the range of -3 to (-5) kcal/mol$Å. The weak van der Waals and London Dispersion
forces between neutral atoms contribute approximately -0.5 kcal/mol$Å to the %G°. A
hydrophobic interaction between a hydrophobic residue in the target and a hydrophobic
moiety in the structure of the drug can improve binding by 0.7 kcal/mol$Å (86). The
pharmacophore point definitions are often consistent with these interaction types.
Structure-Based Pharmacophore Model Development
Structure-based pharmacophores are useful when there is a three-dimensional
crystal structure or homology model that can be used to define features responsible for
biological activity. The docked conformations of crystallized ligands or known ligands
are superposed to generate the pharmacophore. Our preliminary LPA5 antagonist
structure-based pharmacophore models, shown in Figure 7, were developed from two
different superpositions using combinations of three LPA5 antagonists. H2L 5765834
(Compound 1) was originally identified as an LPA3 receptor antagonist, however it
emerged as an LPA5 receptor full antagonist (64) through LPA receptor selectivity
screening by Dr. James Fells at the University of Tennessee Health Science Center.
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Compound 1 is an LPA1, LPA3, and LPA5 antagonist and has an IC50 at LPA5 of 463nM
with 100% maximal inhibition at 10µM. H2L 5160787 (Compound 2) was identified
through similarity searching in MOE on all compounds in the Genome Research Institute
(GRI) database containing the phthalimide group as in Compound 1. Compound 2 has an
IC50 of 640nM with 50% maximal inhibition at 10µM. H2L 5987411 (Compound 3) was
originally identified from the LPA5 agonist structure-based pharmacophore model (64).
Compound 3 is an LPA4 and LPA5 antagonist and has an IC50 at LPA5 of 3.5µM with
42% maximal inhibition at 30µM. The pharmacophore model shown in Figure 7A was
developed from the docked superposition of the two more potent antagonists, Compound
1 and Compound 2 with the previously published LPA5 model. The pharmacophore
model shown in Figure 7B was developed from the docked superposition of two
antagonists, Compound 1 and Compound 3, with the previously published LPA5 model.
Docking simulations with the previously published homology model (64) were
used to develop structure-based pharmacophore models. Default docking parameters
with the AutoDock4.0 software program were utilized for antagonist structure-based
pharmacophore model development which included 25,000,000 energy evaluations,
27,000 generations, 300 local search iterations, and 10 runs. Docked conformations
generated with carboxylic acid headgroups showing the strongest interactions, as
reflected by having the shortest distances, with residues involved in ligand-recognition in
LPA5 (64)—R78 (R2.60), H160 (H4.64), R261 (R6.62), and R276 (R7.32)—were
selected for pharmacophore model development. The binding energies for Compound 1
ranged from -12.11 to -7.99 kcal/mol$Å and the carboxylic acid headgroups for six of the
ten runs was positioned near the cationic arginines for electrostatic interactions. The
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docked position with the carboxylic acid group positioned near cationic arginines, with a
binding energy of -10.00 kcal/mol$Å, and with one other member in the cluster was
selected for pharmacophore model development. The binding energies for Compound 2
ranged from -10.19 to -7.80 kcal/mol$Å and carboxylic headgroups for two of the ten
runs were positioned near the cationic arginines for electrostatic interactions. The docked
position with the carboxylic acid group positioned near cationic arginines, with a binding
energy of -8.71 kcal/mol$Å, and with one other member in the cluster was selected for
pharmacophore model development because this conformation permitted superposition of
common functional groups with Compound 1 for pharmacophore model development.
The binding energies for Compound 3 ranged from -9.31 to -7.41 kcal/mol$Å and
carboxylic acid headgroups for four of the ten runs were positioned near the cationic
arginines for electrostatic interactions. The docked position with the carboxylic acid
group positioned near cationic arginines, with a binding energy of -7.41 kcal/mol Å, and
with one other member in the cluster was selected for pharmacophore model
development because this conformation permitted superposition of common functional
groups with Compound 1 for pharmacophore model development.
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Structure-Based Pharmacophore Results
The docked complexes of Compound 1 and Compound 2 were superposed to
generate the structure-based pharmacophore model shown in Figure 7A. The
pharmacophore consisted of three features. Feature one (P1) represented as a cyan
sphere, was an anionic point generated from the superposition of docked positions of the
carboxylic acid headgroups from both ligands. Feature two (P2) represented as a pink
sphere, was an acceptor point defined at halfway between the docked positions of the
phthalimide carbonyl groups of Compound 1 and Compound 2. Feature three (P3)
represented as a green sphere, was a hydrophobic feature defined at halfway between the
docked positions of the terminal aromatic rings of Compound 1 and Compound 2.
The docked complexes of Compound 1 and Compound 3 were superposed to
produce the structure-based pharmacophore model shown in Figure 7B. The
pharmacophore consisted of three features. Feature one (P1) represented as a cyan
sphere, was an anionic point defined by the superposition of the docked positions of the
carboxylic head groups from both ligands. Feature two (P2) represented as a pink
sphere, was an acceptor point defined at halfway between the docked position of the
phthalimide carbonyl group of Compound 1 and the amide carbonyl group of Compound
2. Feature three (P3) represented as a green sphere, was a hydrophobic feature defined at
halfway between the docked positions of the terminal aromatic rings of Compound 1 and
Compound 3.
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A.

B.

Compound 1

Compound 2

Compound 3
C.

Figure 7. Preliminary LPA5 antagonist structure-based pharmacophores. Panel
A depicts a structure-based pharmacophore developed from the docked
superposition of Compound 1 (blue stick) and Compound 2 (pink stick). Distance
ranges between pharmacophore points are defined as follows: P1-P2: 5.63 Å;
P2-P3: 6.78 Å; P3-P1: 11.97Å. Panel B depicts a structure-based pharmacophore
developed from the docked superposition of Compound 1 (blue stick) and
Compound 3 (purple stick). Distance ranges between pharmacophore points are
defined as follows: P1-P2: 5.63Å; P2-P3: 6.10Å; P3-P1: 11.29Å. The
molecular structures for Compound 1, Compound 2, and Compound 3 are shown
in Panel C.
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Ligand-Based Pharmacophore
A ligand-based pharmacophore utilizes structures of known active ligands for the
identification of novel leads. Ligand-based pharmacophore modeling in virtual screening
is applicable when there is no experimental structural information on the target and
therefore relies on the structures of known actives. A central assumption of the ligandbased pharmacophore is that compounds bind in a common mode in order to exhibit
similar activity at the target. The ligand-based pharmacophore is therefore generated by
considering flexible alignments of known actives. Pharmacophore feature points are
defined based on the overlay of common features within the molecules flexibly aligned.
The pharmacophore is then screened through chemical databases for candidate ligands
matching both the shape and features of the pharmacophore. The pharmacophore
matches, or hits, are selected for experimental screening.
Ligand-Based Pharmacophore Model Development
We generated multiple ligand-based pharmacophore queries using the
Pharmacophore Elucidator in MOE. The pharmacophore elucidator generates an
exhaustive list of pharmacophore queries based on an input database, or training set, of
both active and inactive compounds. We used a training set of five compounds (Table 3)
to generate multiple pharmacophore queries. The training set consisted of two
experimentally confirmed active antagonists and three experimentally confirmed
inactives. Flexible alignments of the active compounds were generated by a stochastic,
or random, search of conformation to find the best scored alignment of active
compounds. Flexible alignments in MOE approximate molecular shape based on a sum
of Gaussian densities (87, 88). With the pharmacophore elucidation, multiple flexible
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alignments of the active compounds generated by the stochastic search were used to
generate multiple pharmacophore queries.

Table 3. Structures of compounds in ligand-based LPA5 training set. Percent
inhibition of LPA5 responses to 100nM LPA at 10µM is shown.
Name
Structure
% Inhibition
H2L 5765834

100%

Compound 1

H2L 5160787

50%

Compound 2

GRI 386620

NE

Compound 4

H2L 5967126

NE

Compound 5

H2L 6812052

NE

Compound 6

NE indicates no effect at 10µM.
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Table 4. Structures of compounds in test set for ligand-based LPA5 pharmacophore
model evaluation. Percent inhibition of LPA5 responses to 100nM LPA at 10µM is
shown.
Name

Structure

GRI 389728

% Inhibition
40.2%

Compound 7

GRI 129438

40.0%

Compound 8
GRI 124602

35.5%

Compound 9
GRI 384847

35.3%

Compound 10
GRI 909835

34.0%

Compound 11

GRI390189

NE

Compound 12
GRI759388

NE

Compound 13
H2L 5962855

NE

Compound 14
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Table 4. Structures of compounds in test set for ligand-based LPA5 pharmacophore
model evaluation. Percent inhibition of LPA5 responses to 100nM LPA at 10µM is
shown.
Name

Structure

H2L 6434254

% Inhibition
NE

Compound 15

H2L 6503864

NE

Compound 16

NE indicates no effect at 10µM.

Each pharmacophore query was scored based on overlap, overall accuracy
(accuracy), accuracy on actives (acc1), and accuracy on inactives (acc0). The overlap
score defined the quality of the alignment of the actives within the training set and had a
highest value of 1.8335 and a maximum value of 2. The overall accuracy (accuracy) is
defined as the number of actives that matched the query and the number of inactives that
did not match the query divided by the total number of training set compounds, and had a
highest value of 1.000. The accuracy on actives score (acc1) is defined as the number of
actives the query identified divided by the total number of actives in the training set, with
a maximum value of 1.000. The accuracy on inactives (acc0) is defined as the number of
inactive compounds that did not match the query divided by the total number of inactives
in the training set, with a maximum value of 1.000. The purpose of the Pharmacophore
Eludicator is to generate a collection of pharmacophore queries from a training set of
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active and inactive compounds. A quality pharmacophore model overlays most of the
actives well as reflected by overlap scores approaching the number of active compounds
and discriminates actives from inactives as reflected by the high accuracy scores.
Molecular geometries and features within the structures of known active compounds are
related to activity (89).
Ligand-Based Pharmacophore Results
The pharmacophore elucidation generated a total of 1,631 pharmacophore models
and the top 20 scored models based on overlap from the flexible alignments were
evaluated using a test set of ten total compounds shown in Table 4. The test set consisted
of five experimentally confirmed actives and five experimentally confirmed inactives. A
threshold of 30% inhibition or more at a single 10µM test concentration was used to
classify active compounds. Table 5 highlights the performance of the top 20 models
based on accuracy on test set actives and inactives. From the test set evaluation Model 5,
shown in Figure 8, scored highest in accuracy on actives, identifying 60% of the active
compounds and discriminating 80% of the inactive compounds. Model 11, shown in
Figure 9, identified 40% of the actives and discriminated 100% of the inactives. Models
13 and 17, shown in Figure 10, each scored 40% with accuracy on actives and 100% with
accuracy on inactives, however were not selected for use in virtual screening even though
they scored higher than Model 5 with accuracy on inactives. A pharmacophore model is
more useful for screening on the basis of high accuracy on actives, as only compounds
selected as actives by the pharmacophore are likely to be screened. Thus Model 5 is
preferred over models 13 and 17 on the basis of its higher accuracy on actives.
Furthermore, Model 13 consisted of two anionic features and one oxygen feature
positioned around the carboxylic head groups of both ligands preventing distance ranges
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between features encompassing the entire shape of the ligands from the alignment.
Model 17 consisted of two anionic features and two hydrophobic features with overall
shape and distance ranges similar to Model 5. Also model 6, model 15, and model 20
was not selected even though they scored identical to model Model 19 in accuracy on
actives and accuracy on inactives (Table 5). Model 6 was similar in shape and
pharmacophore features to Model 5. Model 15 had multiple pharmacophore features
clustered around the anionic headgroup preventing distances ranges between features that
reflected the entire shape of the alignment. Model 20 was similar in shape and
pharmacophore features to Model 19. Model 19, shown in Figure 11, identified 40% of
the actives and discriminated 80% of the inactives and was unique in shape compared to
Models 5, 11, 13, and 17. Models 5, 11, and 19 were therefore used to screen through
the Timtec database which consisted of 176,825 compounds. The pharmacophore models
identified twenty-seven total hits. More specifically Model 5 identified twenty-one
unique hits, Model 11 identified five unique hits, and Model 19 identified one unique hit.
The Hit2Lead (H2L) and the National Cancer Institute (NCI) databases were searched for
identical compounds to order for experimental activity assay. The H2L compound
screening database consists of approximately 900,000 compounds and NCI database
consists of approximately 250,000 compounds. Table 6 shows structures of the ten
pharmacophore hits that were purchased for experimental screening and the
pharmacological evaluation of these hits at LPA5. All compounds were screened at a
single point 10µM concentration for both agonist and antagonist activity. Compounds
were tested at 10µM for agonism and in combination with 100nM LPA at 10µM for
antagonism.
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Table 5. Test set performance of top twenty ligand-based pharmacophore models.
Models highlighted in bold font represent the models selected for virtual screening.
Model
Accuracy on Actives
Accuracy on Inactives
1. HHH-_1
20%
20%
2. HHHO_1
20%
100%
3. RHHHO_1
20%
100%
4. RHH-_1
20%
80%
5. HH-O_6
60%
80%
6. RH-O_6
40%
80%
7. RHHH-_4
20%
100%
8. RHHO_1
20%
100%
9. RHH-O_1
20%
100%
10. RRHH-_7
20%
40%
11. RH--_2
40%
100%
12. RHHO_5
20%
80%
13. RH--O_3
40%
100%
14. RRHO_1
20%
80%
15. RH--O_2
40%
80%
16. HHH-O_1
20%
100%
17. HH--_3
40%
100%
18. HH--O_3
20%
100%
19. RRHO_5
40%
80%
20. RRH-_7
40%
80%
H indicates hydrophobic feature, R indicates aromatic feature, and O indicates oxygen
feature.
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Figure 8. Pharmacophore model 5 with flexible alignment of actives in training
set. Compound 1 is shown in blue stick and Compound 2 is shown in pink stick.
The four-point pharmacophore consisted of two hydrophobic regions (P1 and P2
as green spheres), an anionic region (P3 as a cyan sphere), and an oxygen region
(P4 as a purple sphere). Distance ranges between pharmacophore points are as
follows: P1-P2: 2.61Å , P2-P3: 11.42Å , P3-P4: 0.85Å , P4-P1: 11.42Å.
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Figure 9. Pharmacophore model 11 with flexible alignment of actives in training
set. Compound 1 is shown in blue stick and Compound 2 is shown in pink stick.
The four-point pharmacophore consisted of an aromatic region (P1 as a blue
sphere), a hydrophobic region (P2 as a green sphere), and two anionic regions (P3
and P4 as cyan spheres) respectively. Distance ranges between pharmacophore
points are defined as follows: P1-P2: 2.72Å; P2-P3: 9.78Å; P3-P4: 1.91Å; P4P1: 11.25Å.
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A.

B.

Figure 10. Pharmacophore models not used in virtual screening. Compound 1 is shown
in blue stick and Compound 2 is shown in pink stick. Panel A shows Model 13. The
five-point pharmacophore consisted of an aromatic feature (P1 as a blue sphere), a
hydrophobic feature (P2 as a green sphere), two anionic features (P3 and P4 as cyano
spheres) and an oxygen feature (P5 as a purple sphere). Distance ranges between
pharmacophore points are as follows: P1-P2: 2.72Å , P2-P3: 9.78Å , P3-P4: 1.91Å ,
P4-P5: 2.18Å, P5-P1: 10.38Å. Panel B shows Model 17. The four-point
pharmacophore consisted of two hydrophobic features (P1 and P2 as green spheres) and
two anionic features (P3 and P4 as cyano spheres). Distance ranges between
pharmacophore points are as follows: P1-P2: 2.65Å , P2-P3: 11.36Å , P3-P4: 2.08Å ,
P4-P1: 9.83Å.
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Figure 11. Pharmacophore model 19 with flexible alignment of two actives in training
set. Compound 1 is shown in blue stick and Compound 2 is shown in pink stick. The
four-point pharmacophore consisted of two aromatic regions (P1 and P2 as blue spheres),
a hydrophobic region (P3 as a green sphere), and an oxygen region (P4 as a purple
sphere) respectively. Distance ranges between pharmacophore points are defined as
follows: P1-P2: 9.98Å; P2-P3: 6.23Å; P3-P4: 9.03Å; P4-P1: 13.20Å.
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Table 6. Pharmacological evaluation of pharmacophore hits screened at LPA5.
Compounds were tested for agonism at 10µM and for antagonism of 100nM LPA.
Name
Structure
%
%
Response Inhibition
NSC 97318
Compound 17

NE

32 ± 0.5

NSC 74512
Compound 18

NE

NE

NSC 4899
Compound 19

NE

19 ± 0.1

NSC 402488
Compound 20

17 ± 0.20 NE

NSC 35609
Compound 21

NE

27± 0.9

NSC 9619
Compound 22

NE

18 ± 0.4

NSC 8679
Compound 23

NE

NE
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Table 6. Pharmacological evaluation of pharmacophore hits screened at LPA5.
Compounds were tested for agonism at 10µM and for antagonism of 100nM LPA.
Name

Structure

%
Inhibition

%
Response

NSC 8674
Compound 24

NE

17 ± 0.1

NSC 9617
Compound 25

NE

37 ± 0.1

NSC 34936
Compound 26

NE

22 ± 1.1

H2L5607859
Compound 27

NE

12 ± 0.3

NE indicates no effect.

All compounds were assayed for agonist and antagonist activity at LPA5 by
monitoring LPA5 intracellular calcium mobilization using the FlexStation II plate reader
in the laboratory of Dr. Gabor Tigyi at the University of Tennessee Health Science
Center. Intracellular calcium mobilization was measured by monitoring the ratio of
fluorescence emission at 510nm in response to excitation at 340nm and 380nm. All
compounds were screened in triplicate at a single point 10µM concentration. Agonist
activity was determined by compound percent response relative to LPA, and antagonist
activity was determined by inhibition of LPA percent response. Although compound 17
produced a 32% inhibition, compound 18 produced an 86% response and compound 25
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produced a 37% inhibition, after analyzing the structures and calcium traces for the
compounds, the responses appeared to result from autofluoresence of the diazirine groups
within the structures of the compounds. Therefore we did not confirm compound 17 and
compound 25 as LPA5 antagonists, nor did we confirm compound 18 as an LPA5 agonist.
However compound 21 produced 27% maximum inhibition at 10µM. Figure 12 shows
compound 21 overlap with pharmacophore model 5.

Figure 12. Compound 21 and pharmacophore model 5.

Structure and ligand-based pharmacophores represent a valuable starting point to
characterizing the charge and shape of the binding pocket where the ligand will interact
to elicit biological activity. Because none of the pharmacophore hits were strong LPA5
activators nor inhibitors, we concluded the training set used to generate the
pharmacophore models was either not structurally diverse enough or was not sufficiently
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conformationally restricted to allow selection of superpositions and feature sets that
reflect the bioactive shapes and interaction sites of the active compounds. Highly similar
lead compounds in which all features match prevents identification of a unique and
limited set of features that are required for activity. For example the partial antagonist
Compound 2 is an isomer of the full antagonist Compound 1. More specifically the only
difference between the two LPA5 antagonists is the carboxylic acid group is positioned
on a terminal pthalimide group in Compound 1 and the carboxylic acid group is
positioned on a terminal aromatic ring in Compound 2. Perhaps a more diverse set of
actives in the training set would have generated pharmacophore queries with more
diverse feature points for virtual screening resulting in pharmacophore hits showing
enhanced experimental activity at LPA5. Therefore an optimized model of LPA5 is
needed to allow the generation of structure-based pharmacophores with greater
confidence.
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PROTEIN MODELING
Numerous drugs on the market target GPCR because of their involvement in
important physiological functions. Hence, pharmaceutical researchers desire structures
of these target proteins for the design and optimization of therapeutic leads. In the
absence of crystal structures, protein homology modeling has served as an interim source
of three-dimensional structure information on GPCR drug-targets. The iterative process
of generating an effective model for use in structure-based drug discovery consists of
homology model development, docking, model validation, and model optimization (77).
Commonly utilized model validation techniques include site-directed mutagenesis and
structure-activity relationship (SAR) studies, both of which were used to obtain a
homology model of LPA5 with predictive power.
Protein Homology Modeling
Protein homology modeling is the process of generating a three-dimensional
structure for a protein of unknown structure based on a homologous protein of known
structure (77). The most reliable models are developed from templates that share high
sequence similarity with the target. Presently across GPCR families, the rhodopsin Class
A receptors are the only class of GPCR which researchers have obtained x-ray
crystallographic data on the seven transmembrane domains (18, 19). Therefore
homology modeling efforts with the use of crystal structures have come from modeling
the seven transmembrane domains of target proteins based on rhodopsin Class A crystal
structure templates (20, 23). GPCR homology models have been used to explain
experimental site-directed mutagenesis data (23, 64) as well as for the identification of
novel ligands (90).
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The process of homology model development consists of target and template
sequence alignment, model development, and geometry optimization. The Molecular
Operating Environment (MOE) is a software program utilized for the development of
protein homology models (85). Prior to model development, the target sequence must be
aligned to the template sequence. Template and target sequence alignment is critical for
ensuring accurate modeling of conserved structural motifs as well as for the overall
quality of the model. The protein databank (PDB) (91) contains a variety of crystal
structures available to serve as templates for homology modeling. An appropriate crystal
structure should be selected for homology modeling based on high sequence identity or
sequence homology to the target protein as well as conserved function. MOE’s protein
alignment tool, Protein Align, optimizes a function based on residue similarity and gap
penalties (92). Residue similarity is computed by applying an amino acid substitution
matrix, used to score the alignment, to pairs of aligned residues. A quality alignment will
place conserved residues within the transmembrane domains at the same position in both
the template and target sequences. The alignment should also cluster amino acids by
hydrophobicity in the target sequence near the same position in the template sequence
and should display no gaps within the transmembrane domains. Due to conformational
flexibility in the loop regions (16) and variability between the known structures, modeled
loop structures are likely to be less accurate than the rest of the model. Hence, gaps are
preferred in the loop regions and can be modeled from appropriate length fragments from
the PDB.
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Model Development
Following sequence alignment, MOE begins the model development process.
MOE builds in the amide backbone and copies identical residues from the template
sequence to the target sequence. The loops are then modeled based on appropriate length
fragments from the PDB that possess the same end-to-end distance and the same number
of residues as in the target molecule. Sidechains are modeled from MOE’s internal
rotamer library. Hydrogens are added and a series of energy minimizations are applied to
the system prior to final model selection. The best scored model can then be analyzed
further by examination of the model’s backbone dihedral angles, phi and psi. The
Ramachandran plots display outlier residues, or residues with unfavorable phi or psi
dihedral angles, and the model can be optimized to correct problems identified by this
analysis.
Methods
The previously published LPA5 homology model (64) was developed based on a
previously published LPA1 receptor model (78, 79, 93). We chose LPA1 as a starting
point because phosphate headgroup recognition in LPA1 has been extensively validated
(9, 93). The preliminary LPA5 model was used to validate LPA phosphate headgroup
interactions, however failed to identify full agonists and antagonists. In order to improve
the model for use in structure-based drug discovery, we utilized a multiple template
strategy in homology model optimization. The sequence of LPA5 has a proline in TM5,
however the sequence of LPA1 lacks the analgous proline. The less than optimal
modeling of TM5 might have contributed to the poor predictive power of the preliminary
model. The proper modeling of the presence or absence of proline is important due to the

!

%*!

structural differences between receptors that have and those that lack proline in TM5. Of
the twelve crystal structures provided in Figure 13, S1P1 lacks the TM5 proline. Figure
13A shows the difference in structure of the S1P1 receptor (colored purple) that lacks the
proline in TM5 (RMSD: 0.853). More specifically, the helical turn above the L5.50 in
S1P1 is not distorted or kinked as is the helical turn above the P5.50 in the other crystal
structures. We therefore remodeled TM5 based on a more homologous template that has
a proline in TM5, the human beta-2 adrenergic receptor (94). Table 7 is representative of
select crystal structure sequence identities and sequence homologies to LPA5. The
crystal structure of the active conformation of the human "2 adrenergic receptor was
chosen to remodel TM5 based the crystal structure’s sequence identity to TM5 in LPA5 at
22.2%. Furthermore, the human "2 adrenergic receptor has an overall sequence identity
and homology to LPA5 at 17.7% and 49.3%, respectively.
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A.
B.
Figure 13. Superposition of 12 GPCR crystal structures. Panel A depicts a
superposition of TM5 with the conserved proline or non-conserved leucine residue.
Panel B shows the ribbon structure of the sphingosine-1-phosphate receptor (PDB ID:
3V2W) colored purple. Turkey beta-1 adrenergic receptor (PDB ID: 2VT4) is colored
magenta, mu opiod receptor (PDB ID: 4DKL) is colored white, kappa-opioid
receptor (PDB ID: 4DJH) is colored tan, human adenosine receptor (PDB ID: 3EML)
is colored orange, human beta-2 adrenergic receptor (PDB ID: 3PDS) is colored blue,
human dopamine D3 receptor (PDB ID: 3PBL) is colored pink. CXCR4 chemokine
receptor (PDB ID: 3ODU) is colored yellow, human histamine H1 receptor (PDB ID:
3RZE) is colored dark green, bovine rhodopsin (PDB ID: 1F88) is colored light green,
human M2 muscarinic receptor (PDB ID: 3UON) is colored cyan, and the human M3
muscarinic receptor (PDB ID: 4DAJ) is colored burgundy.
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Table 7. Select crystal structure comparative analysis to the human LPA5 sequence.
PDB ID

Crystal Structure

Helix 5
Sequence
Identity

Overall
Sequence
Identity

Overall
Sequence
Homology

3V2W

S1P1 Receptor

18.8%

14.2%

45.9%

3ODU

CXCR4 Chemokine Receptor

9.1%

18.3%

52.4%

3PBL

Human Dopamine Receptor

22.6%

15.3%

43.0%

3PDS

Human Beta-2 Adrenergic
Receptor

22.2%

17.7%

49.3%

3RZE

Histamine H1 Receptor

11.4%

16.1%

47.5%

During the preliminary homology modeling, ten models of LPA5 were generated
based on the LPA1 template (17.9% overall sequence identity to LPA5) and the final
model was selected based on the generalized born volume integral which estimates free
energy of hydration using London dispersion (95, 96). The forcefield applied for energy
minimization of our preliminary model was the default MMFF94 (73). The AMBER99
forcefield (71), used for the optimization of protein models, was selected for subsequent
remodeling of TM5. Ten models of helices 4, 5, and 6 were generated based on the
human beta-2 adrenergic crystal structure (94) and the final model was selected based on
the generalized born volume integral. Helices 4, 5, and 6 were remodeled for more
accurate insertion of the remodeled TM5 into the LPA5 model. Remodeled helices 4, 5,
and 6 were then aligned to the preliminary model and remodeled TM5 was joined to the
preliminary model through the creation of two amide bonds. The first amide bond was
created between Leu188 of ECL2 and Leu189 at the top of helix 5 and the second amide
bond was created between Arg220 at the bottom of helix 5 and Pro221 of ICL3. The
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resulting multiple template model was then energy minimized to a 0.05 kcal/mol$Å
gradient.
Results
Following homology model development, Ramachandran plots were analyzed to
identify all unfavorable phi and psi dihedral angles (Figure 14). The majority of the
outlier residues, or residues having unfavorable phi or psi dihedral angles, were located
either in the extracellular or intracellular loops of our optimized model. However
Asp293 (D293) was located in TM7 oriented toward the intracellular domain. This
aspartate residue is a part of the conserved N(D)PXXY motif (97) which is present in the
human LPA1 and human beta-adrenergic receptor sequences. Asp293 is located next to a
Pro294 and because proline residues are known to cause a distortion in the alpha-helix (2,
97), we attribute the unfavorable dihedral angle of Asp293 to the presence of the adjacent
Pro294. It has been established that the perturbation of helical structure in TM7 consists
of added structural flexibility induced by a Asp(N)P or Asp(D)P motif, and a proline kink
(97). Furthermore, critical residues involved in LPA phosphate headgroup recognition
were positioned towards the extracellular space of LPA5 and were remote from Asp293.
Therefore for the results presented in this dissertation, we did not consider Asp293 to
profoundly affect our modeled phosphate headgroup interactions.
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R128
D293
A271

S211
T217

R134
W87

F176
K263

R133

F89

V275

A.

B.

R128
D293
A271

T224
F179

A223
R134
W87
K263
R133

F176
V275
F89

C.

D.

Figure 14. Outlier residues for the preliminary and optimized LPA5 homology models.
Panel A depicts the Ramachandran plot for the preliminary LPA5 model. The 12 outlier
residues are represented as black sticks. The ribbon structure of the preliminary model is
colored cyan and outlier residues are colored purple in Panel B. Panel C depicts the
Ramachandran plot for the optimized LPA5 model. The 13 outlier residues are
represented as black sticks. The ribbon structure of the preliminary model is colored
cyan and outlier residues are colored purple in Panel D. The allowed and the core
regions are represented as black circles and squares, respectively.
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Docking
Automated docking is a computational technique used to predict small molecule
binding at a macromolecule (80). Docking has been utilized to reproduce the geometry
of ligand binding conformations with their crystal structures as well as for predicting
binding energies. While docking has been shown to accurately reproduce binding modes
(80, 82, 83), a limitation of docking is that the calculated binding energies poorly
estimate solvent and entropic effects (83, 98). Binding is a desolvation process and the
transition from ligand-solvent interactions to protein-ligand interactions need to be
considered for more accurate calculations of binding energies. Consistencies between
calculated binding energies and experimental binding studies (83, 98) would allow
accurate predictions of ligand binding energies and enhance structure-based drug design.
However based on reproducibility in protein-ligand shape complementarities, researchers
typically utilize docking to prioritize candidate ligands, or hits, for experimental
screening based on qualitative assessment of modeled protein-ligand interactions
predicted necessary for activity (80). Overall the process of virtual screening by
automated docking is a commonly used computational technique in guiding experimental
assays for drug design (80, 82, 90).
Methods
We utilized AutoDock4.0 (83, 84) for all docking simulations throughout the
optimization process. AutoDock4.0 uses a rapid grid-based energy scoring function for
computing binding energies between the target and ligand. In this approach the target
molecule is embedded in a three-dimensional grid and a probe atom is placed at each
point within the grid (80, 83, 99). The interaction energy between atoms is computed and
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stored to serve as a reference during the evaluation of interaction energies. Interaction
energies are calculated for each type of atom within the ligand (80). AutoDock uses a
semi-empirical free energy forcefield to evaluate ligand conformations throughout the
docking simulation (83, 99, 100) (Equation 3). The forcefield consists of intramolecular
terms for the differences in potential energy between the bound and unbound states of the
ligand and protein, as well as an intermolecular term for the differences in potential
energies between the bound and unbound protein-ligand complex. The change in
conformational entropy is an additional term to the forcefield as there are typically fewer
low-energy conformational states in the bound state relative to the free state. The
forcefield also consists of terms for different interaction types (Equation 4). The
dispersion/repulsion term is for the interaction between any pair of atoms. The hydrogen
bonding potential is for the interaction between a hydrogen bond donor and a hydrogen
bond acceptor. The electrostatic potential is for the interaction between partially charged
atoms. The desolvation potential is for the displacement of water by the ligand (100).

Equation 3 (100)

Equation 4 (100)

AutoDock uses a Lamarckian genetic algorithm for conformational searching and
generates multiple conformations throughout the simulation (80, 83). A Lamarckian
genetic algorithm is based on the concept that individuals adapt to their environment and
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are optimized, or fitted, in their immediate environment before passing their
characteristics on to the next generation (101, 102). Every generation a population of
trial conformations is computed and individual conformations search their local
conformational space for local minima and pass this information on to later generations.
An analysis of the predicted binding energies as well as the consistency of the docked
conformations, or clustering, is performed to identify the best protein-ligand
conformation.
We optimized the model by energy minimizing the preliminary LPA5 and LPA
model complex, shown in Figure 15A, to a (0.05 kcal/mol$Å) gradient using the
AMBER99 forcefield. Subsequent optimization through the remodeling of TM5 is
shown in Figure 15B. Default docking parameters were used with the multiple template
model shown in Figure 15B except energy evaluations (14.0 x 1010), number of
generations (80,000), local search iterations (8,000), and number of runs (50). The
number of generations and number of runs were increased to 100, 000 and 100 to obtain
the model complexes presented in Figure 16.
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A.
B.
Figure 15. LPA5 and LPA model complexes. The single template model complex with
LPA is shown in Panel A. The docked conformation of LPA 18:1 is shown in ball and
sticks. Critical residues involved in phosphate headgroup recognition are colored cyan.
Hydrophobic residues selected for mutation to investigate the environment of the
carbonyl oxygen are colored yellow. The multiple-template model complex with LPA is
shown in Panel B. The docked conformation of LPA 18:1 is shown in ball and sticks.
Critical residues involved in phosphate headgroup recognition are colored cyan.
Hydrophobic residues selected for mutation to investigate the environment of the
carbonyl oxygen are colored yellow.
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Molecular systems have both global and local minima on their potential energy
surfaces and geometry optimization utilizes forcefields to direct a search toward a
structure corresponding to a local minimum on the potential energy surface. The process
is referred to as geometry optimization, or energy minimization. We utilized both the
AMBER and CHARMM forcefields for the geometry optimization of the multiple
template model. The AMBER forcefield (71, 72) was selected to remodel TM5 based on
its protein backbone dihedral parameter and the CHARMM forcefield (66, 67) was
selected for the geometry optimization of the docked complexes based on its lipid
parameter. Although a variety of forcefields are suitable for the modeling of proteins
such as the AMBER, GROMOS, and OPLS-AA, the CHARMM forcefield is applicable
to protein-lipid complexes and has proven successful in reproducing experimental results
(66, 67). Selection of an appropriate forcefield is important for the modeling of proteinligand interactions to predict or explain experimental results.
Results
Table 8 highlights the experimentally determined agonist potencies of LPA 18:1,
AGP 18:1, and OTP 18:1, Farnesyl monophosphate (FMP), and N-arachidonylglycine
(NAG). We utilized docking studies with LPA 18:1, AGP 181:1, and OTP 18:1 ligands
to investigate the AGP 18:1 preference in LPA5 relative to LPA 18:1 and OTP 18:1. The
docked conformations for LPA 18:1, AGP 18:1, and OTP 18:1 are shown in Figure 16
and the corresponding modeled interaction distances in angstroms (Å) between the
ligands and mutated residues are reported in Table 9. The optimized model, places the
carbonyl oxygen of LPA in close proximity to the sidechain of L189 (L5.41) at 3.61Å.
The model placed the phosphate group of LPA near R78 (R2.60), R261 (R6.62), and
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R276 (R7.32) for electrostatic interactions and the hydroxyl group of the glycerol
backbone docked near the sidechain of H160 (H4.64) at 2.82Å suggesting a possible
hydrogen bonding interaction (Figure 16C and Table 9). The AGP 18:1 and OTP 18:1
headgroups docked lower in the pocket relative to the headgroup of LPA 18:1 suggesting
stronger interactions between AGP and OTP headgroups with R78 (R2.60), and H160
(H4.64) relative to R261 (R6.62) and R276 (R7.32). Interaction distances were greater
than 4Å between the ligands with T97, Q102, and K185 which suggested T97, Q102, and
K185 are not critical for ligand recognition. The model placed the hydrocarbon chains
for all ligands near F71 (F2.53) at less than 4.5Å and near M105 (M3.36) at less than 4Å
which suggests these hydrophobic residues participate in hydrophobic interactions during
ligand binding. The LPA docked conformation shown in Figure 16A exhibited an -8.14
kcal/mol$Å binding energy (0.37 kilocalories from lowest binding energy) and was a
member of the largest cluster of docked poses with ten total members in the cluster. The
AGP 18:1 docked conformation shown in Figure 16B exhibited a binding energy of -7.86
kcal/mol$Å (0.77 kilocalories from lowest binding energy) and did not cluster with other
docked poses. The OTP docked conformation shown in Figure 16C exhibited a binding
energy of -8.05 kcal/mol$Å (0.52 kilocalories from lowest binding energy) and was part
of a 15 member cluster. All complexes were geometry optimized with the CHARMM27
forcefield (67) to a 0.05 kcal/mol$Å gradient.
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Table 8. Structures and pharmacological evaluation of LPA5 agonists. EC50 values
are the averaged values from six independent experiments. SD indicates standard
deviation and NS indicates not saturated at highest concentration tested, 10µM.
Agonist
EC50 (nM)
Emax (%)
150 ± 33

100

25 ± 14

107 ± 1.7

38 ± 11

115 ± 1.4

49 ± 13

60 ± 2.3

40 ± 15

102 ± 5.2

NS

32 ± 0.57

LPA

AGP

OTP

FMP

FPP

NAG
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A.

B.

C.

Figure 16. LPA5 and ligand model complexes. LPA 18:1 is shown in Panel A, AGP
18:1 is shown in Panel B, and OTP 18:1 is shown in Panel C. Docked ligands are
represented as ball and sticks and critical residues involved in headgroup recognition are
colored cyan. Additional residues mutated for model validation are colored blue and
hydrophobic residues are colored yellow.

Table 9. Modeled interaction distances (Å) between mutated residues in WT
optimized model, shown in Figure 16 and ligands.
R78 H160 R261 R276 T97 Q102 K185 F71 F101 M105
LPA

2.62 2.82

4.20

3.60

4.84 5.73

4.41

3.83 6.52

3.56

AGP 2.43 2.46

5.53

5.31

4.95 5.81

4.77

4.39 5.42

3.91

OTP 2.46 2.49

5.35

5.02

5.11 6.70

4.82

3.71 5.99

3.69

Model Validation
Model validation is critical for obtaining an effective homology model to use in
virtual screening. Homology models are optimized based on experimental studies to
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provide confidence in the model for use in docking simulation. Common model
validation techniques include site-directed mutagenesis and structure-activity relationship
(SAR) studies. We validated phosphate headgroup recognition in LPA5 (64) by sitedirected mutagenesis and have utilized our optimized model as a guide in investigating
the alkyl-LPA preference in LPA5.
Computational Selection of Mutation Sites
To investigate the AGP 18:1 preference in LPA5 relative to OTP 18:1 and LPA
18:1, we selected the LPA 18:1 docked conformation, shown in Figure 16, which
displayed phosphate headgroup interactions most consistent with our prior mutagenesis
data (64). Our prior investigation proved R78 (R2.60) to be critical for LPA phosphate
group recognition because mutation of position 78 to an asparagine (N) abolished
receptor activity. We also proved H160 (H4.64), R261 (R6.62) and R276 (R7.32) to be
involved in LPA recognition, with position 160 most likely participating in a hydrogen
bonding interaction with the hydroxyl group of the glycerol backbone which is not
present in OTP 18:1. The model also suggests R276 (R7.32) and (R261) R6.62
participate in electrostatic interactions with the polar phosphate group of LPA (64).
Based on the pharmacological evaluation of known LPA5 agonists (Table 8),
LPA5 shows a preference for AGP 18:1 relative to OTP 18:1 and LPA 18:1. We
hypothesize that the presence of the carbonyl group in LPA contributes to the higher EC50
value of LPA at 150nM relative to the EC50 values of OTP and AGP at 38nM and 25nM
(Table 8). Docking simulations with the wildtype (WT) optimized model suggests the
polar carbonyl moiety in LPA to bind in close proximity to the non-polar sidechain of
L189 (L5.41) at 3.61Å (Figure 16C). This is an entropically unfavorable interaction,
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which perhaps contributes to the higher EC50 of LPA relative to AGP and OTP. Modeled
interaction distances (Å) between ligands and mutated residues are reported in Table 9.
All headgroups showed strong interactions with R78 and H160 at consistently less than
3Å, which suggests R78 and H160 are residues involved in ligand recognition. Weaker
interactions manifested as longer interatomic distances (Table 9) were observed with
R261 and R276 which suggests R261 and R276 have less impact on ligand recognition
relative to R78 and H160. More specifically, the model predicted R261 and R276 to be
more critical for LPA headgroup recognition based on interatomic distances of less than
4.5Å, relative to AGP and OTP ligands which displayed interatomic distances of greater
than 5Å. Furthermore, the model predicted weaker interactions for all ligands with T97,
Q102, and K185 with interatomic distances greater than 4.5Å which suggested T97,
Q102, and K185 are not essential for ligand recognition. The model predicted
hydrophobic interactions with M105 and F71 based on interatomic distances consistently
less than 4Å with M105 and less than 4.5Å with F71. Weaker hydrophobic interactions
were predicted with F101 with interatomic distances greater than 5Å, and thus the model
predicted M105 and F71 to be more critical for hydrophobic interactions with the ligands
relative to F101. The modeled interaction distances predicted the EC50 of OTP 18:1 and
LPA 18:1 to increase more than the EC50 of AGP 18:1 with the F71 and M105 mutants
(Table 9).
The model predicted F71N and M105N to decrease the potency of AGP, OTP, and
LPA because of the entropically unfavorable interaction between the polar sidechain of
asparagine and the non-polar hydrocarbon chains of AGP, OTP, and LPA. Based on the
modeled interatomic distances (Table 9), we predicted residues having stronger
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interactions with the hydrocarbon chain to exhibit a greater decrease in potency. More
specifically, M105N was predicted to decrease potency more than F71N because
interatomic distances were consistently less than 4Å to the three ligands. The F71N
mutant was also predicted to decrease potency of AGP, OTP, and LPA however we
predicted the EC50 of F71N to be higher than the EC50 of the M105N mutant because of
the longer interatomic distances with F71N relative to M105N. F101A and F101W
mutants were predicted to exhibit similar activity to WT with AGP, OTP, and LPA
because of the maintained hydrophobic sidechains. However the F101A mutant was also
predicted to provide more space for ligand binding relative to the F101W mutant.
Models were developed for LPA5 F71N, F101A/N/W, and M105N to aid in the
interpretation of the experimental mutagenesis results. The models were generated by
mutating one residue from the LPA 18:1 and LPA5 model complex and energy
minimizing the mutant model complex to a RMSG of 0.00001 kcal/mol$Å using the
CHARMM27 forcefield. LPA 18:1 and AGP 18:1 were then redocked into the mutant
models and the complexes were further geometry optimized using the CHARMM27
forcefield.
Molecular dynamic simulations were performed on AGP 18:1 and LPA 18:1 WT
and mutant model complexes and the OTP 18:1 WT complex with the AMBER 10
software program to assist in the interpretation of the experimental mutagenesis results.
All systems were investigated using implicit solvation (96, 103). All complexes were
energy minimized for 6000 cycles. The systems were warmed from 0K-300K over
200ps, with the salt concentration set to 1M, and the solvent dielectric constant set to 3.
The systems were equilibrated at 300K for 1ns with a production run of 10ns at 300K and
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a nonbonded cutoff of 12Å. The ff99SB and the General AMBER Force Field (GAFF)
forcefields were applied to the simulations and bonds involving hydrogen were held
fixed.
Site-Directed Mutagenesis Methodology
Mutants were made with either the polymerase chain reaction (PCR) overlapextension method or the Quikchange II XL mutagenesis kit. Dr. Yuko Fujiwara assisted
in the mutagenesis study by generating the R78N, T97A, Q102A, K185A, H160A,
R261A, R276A, and M105N mutants with the PCR overlap-extension method. I
generated the F71N and F101A/N/W mutants using the QuikChange II XL mutagenesis
kit. The denaturing, annealing, and extending temperatures for the PCR overlapextension method were 92°C, 60°C, and 72°C. The denaturing, annealing, and extending
temperatures for the QuikChange II XL mutagenesis kit method were 95°C, 60°C, and
68°C.
Polymerase Chain Reaction (PCR) Overlap-Extension Method
The polymerase chain reaction (PCR) is the process of DNA amplification by
repeated cycles of heating and cooling for DNA denaturation and the enzymatic
amplification of DNA. Specifically the DNA is heated to melt, to denature it, and is then
cooled to anneal the synthetic oligonucleotide primers. After addition of
deoxynucleoside triphosphates (dNTP) and DNA polymerase, the mutant strand is
synthesized. Mutant primers were purchased from Invitrogen. The T7 forward and BGH
reverse universal primers were utilized in mutant strand synthesis. The universal primers
and forward and reverse mutant primers were used in two PCR reactions that amplified
two fragments of the target gene (Figure 17). The fragments were then duplexed in a
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successive PCR for mutant DNA amplification. The ECORI and NOT1 restriction
enzymes were used to cut the PCR product and the pcDNA3.1 vector. The PCR product
was ligated into the vector using T4 ligase and the WT and mutant plasmids were
transiently transfected into RH7777 cells.
QuikChange II XL Mutagenesis Kit
The QuikChange II XL kit is designed for site-directed mutagenesis. Sitedirected mutations were performed using the high-fidelity PfuUltra DNA polymerase, a
double-stranded LPA5 DNA (dsDNA)-FLAG tagged template, and two oligonucleotide
synthetic primers that were extended during mutant strand synthesis. Mutant strands
were synthesized by thermal cycling in which the LPA5 DNA template was denatured,
the mutagenic primers were annealed, and the primers were extended with the Pfu Ultra
DNA polymerase resulting in a mutant plasmid containing staggered nicks (Figure 18).
Following mutant strand synthesis, the WT methylated and hemimethylated DNA strands
were digested with the Dpn I endonuclease and the mutant plasmid was transformed into
XL10-Gold ultracompetent cells for nick repair.
Transient Transfections and Measurement of Intracellular Calcium Mobilization
Dr. Yuko Fujiwara performed all transient transfections of LPA5WT and mutants
presented in this dissertation. The LPA5WT and mutant plasmids were transiently
transfected into RH7777WT cells using the Effectene Transfection Reagent. RH7777WT
cells (2.0 x 106) were plated onto 60-mm dishes and incubated overnight. The following
morning, the RH7777WT cells were transiently transfected with LPA5 and the mutant
plasmids and the culture medium was changed four hours later for further overnight
incubation. The transfected cells were replated onto 96-well plates the following
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evening. I tested the mutant responses to AGP 18:1, OTP 18:1, and LPA 18:1 by
monitoring intracellular calcium mobilization. The next morning the transfected cells
were serum starved for four hours with Krebs Buffer and were then loaded with Fura2AM indicator dye. Intracellular calcium mobilization in response to LPA was
monitored using the FlexStationII plate reader by measuring the ratio of fluorescence at
510nm in response to excitation at 340nm and 380nm, respectively. Dr. Yuko Fujiwara
performed all cell surface expression experiments (64). Cell surface expression of LPA5
and its mutants was confirmed by flow cytometric analysis provided in Table 10 (64).

Table 10. Cell surface expression of WT and LPA5 mutant receptors determined by
flow cytometry using anti-FLAG antibody staining in transiently transfected
RH7777 cells.
Receptor Constructs
Anti-FLAG-stained cells (% total cells)
pcDNA3.1 vector

<3.0

Wild type

24.3-49.0 (n = 9)

R78 (R2.60N)

22.5

T97 (T3.28A)

63.1

Q102 (Q3.33A)

66.9

H160 (H4.64A)

24.0

H160 (H4.64Q)

61.7

K185 (K5.37A)

35.5
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Table 10. Cell surface expression of WT and LPA5 mutant receptors determined by
flow cytometry using anti-FLAG antibody staining in transiently transfected
RH7777 cells.
R261 (R6.62A)
50.1
R276 (R7.32A)

42.8

R261/R276 (R6.62A/R7.32A)

48.2

F71 (F2.53N)

8.1

F101 (F3.32A)

30.6

F101 (F3.32N)

12.7

F101 (F3.32W)

20.9
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Figure 17. Site directed mutagenesis by PCR overlap extension method. Forward
mutant (FM) and Reverse mutant (RM) with BGH reverse and T7 forward universal
primers anneal to the target gene in separate PCR reactions. The fragments are then
combined in a successive PCR for gene amplification. Restriction enzymes (RE) cut
the plasmid and PCR product and T4 ligase is used to combine PCR product and
plasmid yielding the mutant plasmid DNA.

A.

B.

C.

Figure 18. QuikChangeII XL mutagenesis method. Mutant strand synthesis by
thermal cycling is shown in Panel A. Template digestion is shown in Panel B.
Mutant plasmid to be transformed is shown in Panel C.
!
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3.2.3. Results

Results
The overall protein structure for each protein-ligand complex was stable during
the course of the MD simulations. A plot of the average RMSD over the course of the
10ns simulation relative to the LPA 18:1 and WT model complex starting structure is
provided in Figure 19. The RMSD values for the TM bundle relative to the starting
structure averaged over the last nanosecond of the simulation is reported for each
complex in Table 11. The RMSD values suggests there was not much structural change
in the protein from the starting structures and the complexes were stable over time. The
ligand positions were stable over time for all of the protein-ligand complexes except for
AGP 18:1 and LPA 18:1 with F101A mutant models. More specifically, the hydrocarbon
tails of AGP 18:1 and LPA 18:1 with the F101A mutant model were extended into the
pocket at the start of the simulation, however curled to a more optimal position over the
course of the simulation.

Figure 19. RMSD plot of LPA 18:1 and WT model complex over 10ns simulation.
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Table 11. Average root mean square deviation (RMSD) (Å) values for each protein
TM bundle relative to each starting structure.
F71N
F101A
F101N
F101W
M105N
WT
(F2.53N)

(F3.32A)

(F3.32N) (F3.32W)

(M3.36N)

LPA 18:1

4.4

4.3

4.1

6.1

5.4

4.3

AGP 18:1

4.4

4.3

4.5

4.2

5.7

4.4

OTP 18:1

--

--

--

--

--

4.4

Table 12 is representative of the average protein-ligand interaction distances over
the course of the 10ns simulation for each model complex. Among the WT complexes,
the MD simulations positioned the phosphate group of LPA 18:1 and AGP 18:1 in close
proximity to R78, H160, R261, and R276 with interatomic distances approximately 4Å or
less (Table 12). This phosphate group position is somewhat closer to R261 and R276 for
the LPA and AGP complexes, however an electrostatic interaction was lost between the
thiophosphate group of OTP 18:1 and R261 with an observed interaction distance of
13.52Å (Table 12) relative to an interaction distance of 5.35Å obtained from the docking
simulation (Table 9) although the reduced distance R276 relative to the starting geometry
also occurs for OTP. Weaker interactions were observed between M105 and F71 with all
ligands at greater than 4Å and 7.5Å. The MD simulations predicted stronger contact
between F101 with AGP 18:1 and LPA 18:1 with interatomic distances of 3.72Å and
3.93Å. Average distances are representative of interactions between the hydrophobic
tails of the ligands with aromatic or hydrophobic sidechains of F71, F101, and M105.
Average agonist potencies and efficacies for WT and mutants are provided in Table 13.
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Table 12. Average protein-ligand interaction distances (Å) over the course of the
10ns simulation for each model complex.

!

WT
LPA
AGP
OTP

R78
3.11
2.76
2.86

H160
3.13
3.10
4.91

R261
3.04
4.02
13.52

R276
2.99
3.56
3.07

F71
7.83
8.26
9.29

F71N
LPA
AGP

R78
2.76
2.73

H160
3.91
4.93

R261
2.77
4.73

R276
2.78
2.79

F71N
4.72
4.79

F101A
LPA
AGP

R78
3.34
3.09

H160
4.21
3.83

R261
15.86
7.81

R276
3.09
3.07

F71
4.29
5.05

F101N
LPA
AGP

R78
2.72
2.72

H160
3.51
3.94

R261
15.71
12.77

R276
2.77
2.96

F71
3.95
4.52

F101W
LPA
AGP

R78
3.83
2.77

H160
5.16
2.90

R261
5.43
10.94

R276
2.77
2.81

F71
4.11
4.41

M105N
LPA
AGP

R78
3.33
2.81

H160
4.44
2.98

R261
18.40
13.68

R276
15.02
2.72

F71
4.67
8.43
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Table 13. Average EC50 and Emax values for LPA5WT and mutants. Each mutant was
tested on LPA 18:1, AGP 18:1, and OTP 18:1 and is separated by blank lines. SD
indicates standard deviation and n indicates number of independent experiments.
LPA 18:1_LPA5WT
AGP 18:1_LPA5WT
OTP 18:1_LPA5WT

EC50 and SD
150nM +/- 33nM
25nM +/- 14nM
38nM +/- 11nM

Emax (%)
100
107 +/- 1.7
115 +/- 1.4

n
n=6
n=6
n=6

LPA 18:1_R78N (R2.60N)
AGP 18:1_R78N (R2.60N)
OTP 18:1_R78N (R2.60N)

NE
NE
NE

NE
NE
NE

n=1
n=1
n=1

LPA 18:1_R261/R276A (R6.62/R7.32A)
AGP 18:1_R261/R276A (R6.62/R7.32A)
OTP 18:1_R261/R276A (R6.62/R7.32A)

NE
NE
NE

NE
NE
NE

n=1
n=1
n=1

LPA 18:1_R261A (R6.62A)
AGP 18:1_R261A (R6.62A)
OTP 18:1_R261A (R6.62A)

469nM +/- 79nM
128nM +/- 14nM
113nM +/- 15

128 +/- 0.43
132 +/- 1
127 +/- 1

n=1
n=1
n=1

LPA 18:1_R276A (R7.32A)
AGP 18:1_R276A (R7.32A)
OTP 18:1_R276A (R7.32A)

NE
NE
NE

NE
NE
NE

n=1
n=1
n=1

LPA 18:1_K185A (K5.37A)
AGP 18:1_K185A (K5.37A)
OTP 18:1_K185A (K5.37A)

196nM +/- 149nM
55nM +/- 5nM
24nM +/- 4nM

92 +/- 5.2
84 +/- 1.4
90 +/- 0.8

n=1
n=1
n=1

LPA 18:1_H160A (H4.64A)
AGP 18:1_H160A (H4.64A)
OTP 18:1_H160A (H4.64A)

334nM +/- 75nM
64nM +/- 16nM
443nM +/- 141nM

101 +/- 6.3
103 +/- 7.3
145 +/- 0.7

n=1
n=1
n=1

LPA 18:1_H160Q (H4.64Q)
AGP 18:1_H160Q (H4.64Q)
OTP 18:1_H160Q (H4.64Q)

162nM +/- 70nM
41nM +/- 20nM
65nM +/- 11nM

135 +/- 1.1
136 +/- 0.9
135 +/- 0.2

n=3
n=3
n=3

LPA 18:1_Q102A (Q3.33A)
AGP 18:1_Q102A (Q3.33A)
OTP 18:1_Q102A (Q3.33A)

276nM +/- 83nM
46nM +/- 8nM
45nM +/- 5nM

94 +/- 2.4
98 +/- 1
100 +/- 0.5

n=1
n=1
n=1

LPA 18:1_T97A (T3.28A)
AGP 18:1_T97A (T3.28A)
OTP 18:1_T97A (T3.28A)

109nM +/- 26nM
197nM +/- 28nM
87nM +/- 19nM

175 +/- 1.3
162 +/- 1.6
192 +/- 1.2

n=1
n=1
n=1

LPA 18:1_F71N (F2.53N)
AGP 18:1_F71N (F2.53N)
OTP 18:1_F71N (F2.53N)

1.06#M +/- 112nM
374nM +/- 55nM
68nM +/- 6nM

63 +/- 0.5
94 +/- 0.8
110 +/- 0.5

n=2
n=2
n=2
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Table 13. Average EC50 and Emax values for LPA5WT and mutants. Each mutant was
tested on LPA 18:1, AGP 18:1, and OTP 18:1 and is separated by blank lines. SD
indicates standard deviation and n indicates number of independent experiments.
LPA 18:1_F101A (F3.32A)
AGP 18:1_F101A (F3.32A)
OTP 18:1_F101A (F3.32A)

1.36#M +/- 138nM
65nM +/- 27nM
39nM +/- 10nM

90 +/- 13.5
103 +/- 4
144 +/- 2.3

n=2
n=2
n=2

LPA 18:1_F101N (F3.32N)
AGP 18:1_F101N (F3.32N)
OTP 18:1_F101N (F3.32N)

1.18#M +/- 324nM
351nM +/- 143nM
65nM +/- 23nM

67 +/- 2.4
86 +/- 3.4
107 +/- 2.5

n=2
n=2
n=2

LPA 18:1_F101W (F3.32W)
AGP 18:1_F101W (F3.32W)
OTP 18:1_F101W (F3.32W)

NE
142nM +/- 150nM
212nM +/- 118nM

NE
79 +/- 1.6
72 +/- 0.7

n=2
n=2
n=2

LPA 18:1_M105N (M3.36N)
AGP 18:1_M105N (M3.36N)
OTP 18:1_M105N (M3.36N)

3.30#M +/- 586nM
121nM +/- 72nM
142nM +/- 80nM

70+/- 4
100 +/- 3.8
99 +/- 3.6

n=2
n=2
n=2

Table 13 highlights the response of LPA5WT and several mutants to LPA 18:1,
AGP 18:1, and OTP 18:1 ligands. WT and mutants were tested in triplicate and the mean
values from each experiment were fit using KaleidaGraph. The average WT LPA, AGP,
and OTP EC50 values were obtained from six independent experiments and had EC50
values of 150nM for LPA, 25nM for AGP, and 38nM for OTP (Table 8). R78N, R261A,
R276A, T97A, Q102A, and K185A mutants were previously used to validate LPA
phosphate group recognition (64) and were tested using AGP and OTP. The maximal
response of LPA 18:1 was set to 100% on each plate and the ligands responses were
normalized to LPA responses on each plate. The R78N and R276A mutations abolished
receptor response to all three ligands confirming that R78 and R276 are critical for
headgroup recognition. R261A increased the LPA EC50 to 469nM (WT EC50 = 150nM)
and increased the EC50 values of AGP 18:1 and OTP 18:1 to 128nM (WT EC50 = 25nM)
and 113nM (WT EC50 = 38nM). The average interaction distances obtained between the
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headgroups of all ligands with R261 suggests R78, R261, and R276 are involved in
ligand binding (Table 12) however only R78 and R276 are critical for receptor activation
(Table 13). Therefore mutant models of R78, R261, and R276 need to be developed to
investigate their possible involvement in ligand binding. Also radioligand binding assays
need to be performed to investigate how much each arginine residue contributes to ligand
binding. Perhaps R261 binds the headgroup however contributes less to receptor
activation because of its position higher in the extracellular loop relative to R78, and
R276 (Figure 16).
For the F71N mutant, the LPA EC50 shifted to 1.06µM (LPA WT control EC50 =
150nM) and the AGP EC50 shifted to 374nM (AGP WT control EC50 = 25nM). The
ligand positions were stable over time, however the decrease in potency for both ligands
can be attributed to unfavorable interactions between the hydrophobic tails with F71N.
More specifically, an entropically unfavorable interaction was observed between the
polar sidechain of asparagine at position 71 and the non-polar hydrophobic tails of LPA
and AGP at 4.72Å and 4.79Å (Table 12). The AGP Emax was similar to WT at 94%
(Table 13), however the LPA Emax decreased to 63%. The results suggest F71 is involved
in hydrophobic interactions contributing to both AGP and LPA recognition.
For the F101A mutant, the LPA EC50 shifted to 1.36µM (LPA WT control EC50 =
150nM) and the AGP EC50 of 65nM was comparable to the AGP WT control at 25nM.
The MD results suggest an electrostatic interaction was lost between the phosphate group
of LPA and R261, which is consistent with the increase in LPA EC50 from 150nM to
1.36µM. For the F101N mutant, the LPA EC50 shifted to 1.18µM (LPA WT control EC50
= 150nM) and the AGP EC50 shifted to 351nM (AGP WT control EC50 = 25nM). The
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ligand positions were stable over time, however similar to the F71N mutant, the decrease
in potency for both ligands can be attributed to the entropically unfavorable interaction
between the polar asparagine sidechain and the hydrophobic tail. Furthermore
electrostatic interactions were lost between the phosphate groups of both ligands with
R261 (Table 12). The LPA Emax also decreased to 67% when tested on F101N which
suggests F101 contributes to hydrophobic interactions that result in receptor activation.
Figure 23 is representative of AGP and LPA binding to the F101N mutant over the last
nanosecond of the molecular dynamics simulation. For the F101W mutant, the receptor
did not recognize LPA (LPA WT control EC50 = 150nM) and the AGP EC50 shifted to
142nM (AGP WT control EC50 = 25nM). The ligand positions were stable over time
however the LPA model complex with F101W displayed an RMSD of 6.1Å compared to
the WT complex RMSD of 4.3Å (Table 11). Therefore the bulky tryptophan sidechain
introduced at position 101 might have caused an overall structural change in the protein
that contributed to the lack of receptor response to LPA due to unfavorable interactions
between the bulky sidechain and LPA. This protein structural impact was liganddependent, as the AGP complex RMSD of 4.2Å was very similar to the corresponding
WT complex RMSD of 4.4Å. In the AGP complex, an electrostatic interaction was lost
between the phosphate group of AGP and R261 (Table 12) which is consistent with the
increase in AGP EC50 from 25nM to 142nM (Table 13).
For the M105N mutant, the LPA EC50 shifted to 3.30µM (LPA WT control EC50
= 150nM) and the AGP EC50 shifted to 121nM (AGP WT control EC50 = 25nM). The
ligand positions were stable over time, however electrostatic interactions were lost
between the phosphate group of LPA and both R261 and R276 (Table 12). The LPA
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Emax decreased to 70% when tested on M105N. Also an electrostatic interaction was lost
between the phosphate group of AGP and R261. The results suggest M105 contributes to
hydrophobic interactions involved in ligand recognition.
Molecular docking was a computational technique utilized in this study to
computationally select residues for mutation and to predict their possible involvement in
ligand recognition. Molecular dynamics was a second computational technique utilized
to assist in the explanation of the experimental mutagenesis results. The docking
simulations with LPA 18:1 correctly identified F71, F101, and M105 as residues involved
in hydrophobic interactions with the hydrocarbon chain of LPA 18:1 based on the
observed 10-fold shift in EC50 for LPA 18:1 upon mutation of these residues to the more
polar asparagines residue (Table 13). AGP 18:1 was also affected by F71N, F101A/N/W,
and M105N (Table 13) as indicated by the increase in EC50 which suggests these residues
are involved in hydrophobic interactions contributing to AGP recognition. The changes
in atomic position in response to kinetic energy added to the modeled complexes were
observed in the molecular dynamic simulations. The molecular dynamics results assisted
in the explanation of the experimental mutagenesis results and provided a visualization of
changes in atomic interactions. More specifically, an increase in EC50 was reflected in
the MD simulations by either a loss of headgroup interactions with R261 (Table 12), or
an entropically unfavorable interaction with a polar sidechain and the non-polar tail.
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LPA5 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) ANALYSIS
The structure-activity relationship (SAR) of LPA5 was limited to only a few LPA
species (54, 59, 60, 104) and other phospholipids prior to our investigation (64). Farnesyl
phosphate and N-arachidonylglycine are other phospholipid agonists of LPA5 (104), and
it had been previously established that AGP is the preferred ligand for LPA5 relative to
LPA (59, 60). Furthermore it has been proven that the optimal chain length for LPA5
activation by AGP and LPA is the 18:1 carbon chain length (59, 60). Recent studies have
proved LPA5 as one of the most abundantly expressed LPA-GPCR in human platelets
(59, 61) and on human mast cells (62). The literature documents an alkyl-LPA preference
in LPA5 relative to acyl-LPA (59), therefore we extended our mutagenesis study to
validate AGP 18:1 and OTP 18:1 headgroup recognition in LPA5 in addition to
hydrophobic interactions in the binding pocket, highlighted in Chapter 3 of this
dissertation. Furthermore we screened several fatty alcohol phosphates (FAP) and fatty
acids at LPA5 for agonist activity. Table 8 highlights the pharmacological evaluation of
known LPA5 agonists. A thorough investigation of structural features necessary for
receptor activation or inhibition could assist in anti-thrombotic or anti-cancer therapeutic
lead discovery. Furthermore, expanding the structure-activity relationship (SAR) of
LPA5 could provide tools to probe signaling pathways of LPA5 underexplored in the
literature.
Fatty Alcohol Phosphate Screening
Fatty alcohol phosphates (FAP) have been reported to possess the minimal
functional groups required for LPA1-3 and PPAR# receptor activity (105). The FAP
structure consists of a phosphate headgroup and hydrocarbon tail, however lacks the
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glycerol backbone present in the alkyl and acyl-LPA species. The literature documents
ligand recognition in the EDG LPA and PPAR# receptors in response to varying FAP
headgroups, chain lengths, and degrees of unsaturation (105). Therefore we investigated
the activity of several FAP analogs at the non-EDG receptor, LPA5. Dr. Veeresh
Gududuru at Rx Bio Inc. provided FAP analogs for agonist screening at LPA5. The FAP
analogs were originally screened at a single point 10µM concentration for agonism.
Compounds exhibiting 50% or greater agonist response at 10µM were tested for agonist
potency using the compound concentration range of 30µM-0µM, displayed in Table 14.
Compounds not exhibiting 50% or greater agonist response are provided in Table 15.
Figure 20 highlights our investigation of the effects of different structural features
on LPA5 activation. The effect of the carbonyl group in LPA 18:1 was originally
investigated by comparison of the EC50 value of LPA 18:1 at 150nM to the EC50 value of
AGP 18:1 at 25nM (Table 8). The effect of the phosphate headgroup and the glycerol
backbone were then investigated by experimental assay of OTP 18:1. OTP 18:1 has a
thiophosphate headgroup and lacks the glycerol backbone (Table 8) and produced a
38nM EC50. AGP 18:1, OTP 18:1, and LPA 18:1 all have cis double bonds at the carbon9 position, although in the OTP structure the relative spacing between the headgroup and
the cis double bond is shorter due to the absence of the glycerol moiety. The effect of
chain length on LPA5 activation was examined using 15:1 (compound 28), 17:1
(compound 29), and 19:1 (compound 30) carbon chain lengths with the cis-double bond
at the carbon-10 position. To determine headgroup preference, the phosphate analog of
compound 29 (compound 31) was tested as well as the phosphate analog of OTP
(compound 32). The trans isomer of compound 32 was also assayed (compound 33) to
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investigate a preference in double bond conformation. The effect of a difluoromethylene
phosphonate and phosphorylthioate headgroups were then compared with the
thiophosphate group of OTP with the assay of compound 34 and compound 35.
Furthermore the effect of chain length was examined by the assay of compounds 36, 37,
and 38 which consisted of 14, 18, and 7 carbon chain lengths. Compound 37 differed
only in absence of saturation relative to compound 35. Using OTP 18:1 as a reference,
we tested the effect of double bond position on activity with the assay of compound 39
which contained a cis-double bond at the carbon-11 position. The effect of chain length
was further examined with the comparison of OTP to compound 40 which had a 16:1
carbon chain length and a cis-double bond at the carbon-9 position. Compound 41,
compound 42, and compound 43 were compounds that differed by both chain length and
double bond position relative to OTP. More specifically, compound 41, compound 42,
and compound 43 had 22:1, 23:1, and 24:1 chain lengths with cis-double bonds at the
carbon-13, carbon-14, and carbon-15 positions. The results of the FAP screening are
provided in Table 14 and Table 15. We also assayed several fatty acids for agonist
activity at LPA5 and the results are provided in Table 16.
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Figure 20. Investigation of the effect of structural features on LPA5 activity.
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Results
Table 14 highlights the pharmacological evaluation of several FAP analogs at
LPA5. Due to high variability in LPA EC50 values as a result of cell condition, ranging
from 67nM to 394nM during the period in which the FAP compounds were assayed, the
LPA EC50 values from each plate were used to normalize the FAP responses to correct
for cellular response variation. Thus the FAP EC50 value was divided by the LPA EC50
value from the same experiment to determine the fold difference value that is reported in
Table 14 for easier comparison between FAP structures assayed using cells at different
passage numbers with differing responses to LPA. Comparison of compounds 28-30
indicate the shorter 15-carbon chain length (compound 28, 2.72 fold higher EC50 than
LPA) is preferred over the longer 17:1 (compound 29, 5.44 fold higher EC50 than LPA)
or 19:1 (compound 30, 5.10 fold higher EC50 than LPA) chain lengths in compounds with
the thiophosphate headgroups and a cis double bond at carbon 10. For the 17:1 chain
length with the cis-double bond at the carbon-10 position, LPA5 shows a preference for
the phosphate headgroup because the EC50 of compound 31 was only 3.24 fold higher
than LPA but the EC50 of compound 29 was 5.44 higher than LPA (Table 14). However
for the 18:1 chain length with the cis-double bond at the carbon-9 position, LPA5 shows a
preference for the thiophosphate headgroup given that OTP 18:1 displayed an EC50 value
of 38nM (0.25 fold the EC50 value of LPA) and Emax of 100% (Table 8) while compound
32 with the phosphate headgroup displayed only a 28% response at 10µM (Table 15).
Furthermore changing the geometry of the double bond at the carbon-9 position to trans
resulted in no effect when tested on LPA5 (Table 15), thus a bend in the ligand binding
pocket is likely at a position 9 carbons from the polar headgroup.
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The difference in headgroup preference observed for the 17:1 cis delta 10
(compound 29 and compound 31) and for the 18:1 cis delta 9 (OTP and compound 32)
can be used to make inferences about the LPA5 binding pocket. In particular, a
thiophosphate group is larger in size than a phosphate group, and is the preferred
headgroup when the bend induced by the cis-double bond is closer to headgroup. The
smaller phosphate group is preferred when the bend induced by the cis-double bond is
farther from the headgroup. These results suggest a fixed distance between the
headgroup binding pocket and the bend in the region of the binding pocket occupied by
the cis double bond in the hydrophobic tail.
Compound 35 differs from OTP in the position of the sulfur atom, and showed
similar potency to LPA (only 1.1 fold higher), but is substantially less potent than OTP.
Thus the thiophosphate headgroup of OTP is strongly preferred over the
phosphorylthioate of compound 35. Compound 34 replaces the sulfur headgroup in
compound 35 with a difluoromethylene group resulting in 41% agonist response at 10µM
for compound 34 (Table 15) in contrast to the full agonism at compound 35 for only 1.11
fold higher EC50 for than LPA (Table 14), with the EC50 value of OTP 0.25 fold the EC50
value of LPA. Thus the phosphorylthioate headgroup is preferred relative to the
difluoromethylene group. This experimental observation suggests LPA5 accommodates
more negative charge in the headgroup binding pocket for optimal receptor activity. The
pka2 value for OTP is 6.0 indicating that the predominant species in solution under the
assay conditions will have a charge of negative two. The pka2 value for compound 35 is
6.5, leading to a reduced population of doubly-charged species for this compound. The
pKa2 value for compound 32 is 6.8, indicating that compound 32 will have the smallest
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proportion of doubly-charged species under the assay conditions. Also, the phosphorusoxygen bond length is 1.45Å and the sulfur-phosphorus bond length is 1.63Å. Therefore
the longer the bond length and the lower the pKa2 value, the stronger the activation which
suggests LPA5 prefers more negatively charged headgroups for receptor activity.
Compound 39 with the 18:1 chain length was 3.92 fold higher than LPA and 6.92
fold higher than OTP, with the EC50 value of OTP 0.25 fold the EC50 value of LPA,
therefore the cis double bond is preferred at the carbon-9 position rather than the carbon11 position. This provides further weight to the fixed distance between the site
interacting with the charged headgroup and the curve accommodating the cis-double
bond described earlier. Compound 40 with the 16:1 chain length was 1.16 fold higher
than LPA and 5.34 fold higher than OTP (EC50 value of OTP 0.25 fold the EC50 value of
LPA), therefore the 18:1 chain length is preferred. Compound 41, Compound 42, and
Compound 43 were also screened at LPA5 for agonist activity. Compound 42 with the
23:1 chain length and cis-double bond at the carbon-14 position is preferred with an EC50
value 1.11 fold higher than LPA relative to the 22:1 (6.72 fold higher than LPA, Table
14) and the 24:1 (Emax only 25%, Table 15) chain lengths with cis-double bonds at the
carbon-13 and carbon-15 positions.
Several fatty acids provided in Table 16 were also screened to investigate the
effect of the carboxylic acid headgroup, the effect of saturation, the effect of chain length,
and the effect of the position of the double bond. However none of the fatty acids
activated the LPA5 receptor which suggests the carboxylic acid group is not the preferred
headgroup for agonist activity. However NAG was a weak partial agonist and the
structure of NAG consists of twenty-three carbon chain length with four cis-double bonds
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at the carbons 8, 11, 14, and 17 positions in addition to an amide group two carbons from
the terminal carboxylic acid headgroup. Therefore the pi electrons in the cis alkenes in
addition to a polar hydrogen bond donor such as the amide hydrogen or hydrogen bond
acceptor such as the amide carbonyl oxygen is needed as well as the carboxylic acid
group for receptor activation due to the limitation that a carboxylgic acid group cannot
become doubly charged. Also compound 20 (Table 6) has the sulfate headgroup with the
twelve carbon saturated chain length and was not a strong agonist (Emax = 17%), therefore
the sulfate group is not preferred for activity. The analogous compound 44 with the
carboxylic acid group and saturated twelve carbon chain (Table 16) did not activate the
receptor at all. The sulfate group, therefore, must offer better ability to interact with
multiple ionic interaction partners in the receptor than the carboxylic acid group even
though both are limited to only a single negative charge. Furthermore compounds 36 (14
carbons, Emax = 30%) and 38 (7 carbons, no receptor response) (Table 15) suggest the
phosphorylthioate headgroup acts similarly to the sulfate headgroup with regards to LPA5
receptor activity, although identical chain lengths are not available for comparison.
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Table 14. Pharmacological evaluation of select FAP analogs. All compounds were
tested on B103 cells stably expressing LPA5. The LPA EC50 was used as a control to
compare to each FAP EC50. SD indicates standard deviation.
Name
Structure
LPA EC50 and SD:
Emax
*Fold
FAP EC50 and SD

(%)

150 ± 33nM:

115 ±

38 ± 11nM

1.4

Compound

174 ± 71nM:

144 ±

28

379 ± 67nM

1.7

Compound

67 ± 16nM:

123 ±

29

365 ± 72nM

1.5

Compound

67 ± 16nM:

137 ±

30

342 ± 124nM

6.3

Compound

279 ± 110nM:

92 ±

31

906 ± 59nM

1.7

Compound

394 ± 125nM:

103 ±

35

438 ± 70nM

0.39

OTP
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Increase
0.25

2.17

5.44

5.10

3.24

1.11

Table 14. Pharmacological evaluation of select FAP analogs. All compounds were
tested on B103 cells stably expressing LPA5. The LPA EC50 was used as a control to
compare to each FAP EC50. SD indicates standard deviation.
Compound
67 ± 16nM:
137 ± 3.92
39

263 ± 197nM

6.3

Compound

174 ± 71nM:

155 ±

40

203 ± 106nM

0.32

Compound

142 ± 98nM:

109±

41

955 ± 127nM

0.13

142 ± 98nM:

121 ±

159 ± 267nM

0.45

Compound

1.16

6.72

1.11

42
*FAP EC50/LPA EC50

Table 15. FAP analogs with % responses at 10µM less than 50%. All compounds
were tested on B103 cells stably expressing LPA5.
Name
Structure
% Response
Compound 32
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28%
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Table 15. FAP analogs with % responses at 10µM less than 50%. All compounds
were tested on B103 cells stably expressing LPA5.
Compound 33
NE

Compound 34

41%

Compound 36

30%

Compound 37

NE

Compound 38

NE

Compound 43

25%
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Table 16. Pharmacological evaluation of select fatty acids at LPA5. All compounds
were tested on B103 cells stably expressing LPA5.
Lauric Acid
NE
NE
Compound 44
Myristic Acid

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

Compound 45
Palmitic Acid
Compound 46
Stearic Acid
Compound 47
Arachidic Acid
Compound 48
Palmitoleic Acid
Compound 49
Oleic Acid
Compound 50
Vaccenic Acid
Compound 51
Linoleic Acid
Compound 52
Arachidonic Acid
Compound 53
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CONCLUSIONS
Ligand recognition in LPA5 was validated using a combination of docking, sitedirected mutagenesis, and SAR studies. We previously validated LPA phosphate group
recognition in LPA5 with site-directed mutagenesis (64) and extended the mutagenesis
study to validate hydrophobic interactions contributing to receptor activity. Additionally
the SAR of LPA5 was expanded to investigate optimal headgroup, chain length, and
double bond position for receptor activity. The results suggest for the 18:1 delta 9 chain
length, the thiophosphate headgroup in the absence of glycerol better accommodates the
bend induced by the double bond in the hydrocarbon tail. The model correctly identified
F71 (F2.53), F101 (F3.32), and M105 (M3.36) as residues involved in LPA hydrophobic
interactions because the EC50 of LPA shifted from 150nM in WT to the micromolar range
when tested on F71N, F101A/N/W, and M105N (Table 13). Additionally, changes in
protein-ligand atomic positions in response to ligand placement in the binding pocket
were modeled with molecular dynamics. The molecular dynamics predict agonist
potency was reduced in response to either an entropically unfavorable interaction
between a polar asparagine sidechain and the hydrocarbon tail of the ligand, or a loss of
LPA or AGP phosphate electrostatic interactions with R261 (Table 12).
Integration of Modeling and SAR
Headgroup interactions and hydrophobic interactions involved in LPA5 activation
were validated using homology modeling, docking, molecular dynamics, and sitedirected mutagenesis. Molecular modeling coupled with experimental mutagenesis
identified three cationic residues—R78 (R2.60), R261 (R6.62), and R276 (R7.32) (Table
13). Mutation of these residues to alanine reduced or eliminated ligand-induced
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activation of LPA5, demonstrating critical roles for these residues in receptor activation.
The SAR results demonstrate a single negatively charged headgroup is not sufficient to
stabilize the cationic binding pocket for full receptor activity. More specifically, NAG is
a 32% activator of LPA5 (Table 8) and consists of a terminal carboxylic acid group, a
polar amide group, and a twenty-three carbon chain length with four cis double bonds at
the carbons 8, 11, 14, and 17 positions. The fatty acid structures consist of a carboxylic
acid headgroup of varying chain lengths between twelve and twenty carbons and degrees
of unsaturation (Table 16), however lack the polar amide group present in the weak
partial agonist, NAG. In particular, compound 53 consists of a twenty carbon chain
length with four cis-double bonds at the carbons 5, 8, 11, and 14 positions (Table 16).
Compound 53 also lacks the amide functional group and has a cis-alkene positioned three
carbons closer to the carboxylic acid headgroup relative to NAG. Because shorter chain
lengths with other headgroups activate the receptor (18:1 carbon chain length in OTP)
and compounds 49-52 have varying double bond positions and did not activate the
receptor (Table 16), the presence of the polar amide group in NAG could explain the
functional difference between the fatty acids and NAG. None of the fatty acids activated
the receptor (Table 16) which proved the single negatively charged carboxylic acid group
in the absence of another polar moiety is not sufficient to activate the receptor.
Additionally compound 20 consisted of a single negatively charged sulfate headgroup
and produced only a 17% response (Table 6) which further confirmed the single
negatively charged headgroup is not sufficient to stabilize the cationic binding pocket
formed by R78, R261, and R276.
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Thus multiply charged headgroups better stabilize the cationic binding pocket as
proven by full receptor activity achieved through the binding of LPA (EC50 = 150nM),
AGP (EC50 = 25nM), and OTP (EC50 = 38nM) ligands which consist of polar phosphate
headgroups that can adopt, in varying proportions, a negative two charge at neutral pH.
Additional support for the idea that increased amounts of negative charge contribute
favorably to receptor activation come from comparison of farnesyl monophosphate
(FMP), to farnesyl pyrophosphate (FPP), with maximal negative charges of negative two
and negative three, respectively. FMP is a partial LPA5 agonist with a potency of 49nM,
whereas FPP is a full LPA5 agonist with a potency of 40nM (64). The results presented
in chapter 3 and 4 together demonstrate that the high charge density produced from three
cationic residues (R78, R261, R276) must be balanced by a highly charged anionic ligand
headgroup to elicit receptor activation. The cationic binding pocket in the receptor can
be stabilized by headgroups that are multiply charged at neutral pH and that delocalize
the charge onto multiple atoms during ligand binding leading to receptor activation.
The higher EC50 value of LPA at 150nM relative to AGP at 25nM suggests the
presence of the polar carbonyl group of LPA prevents optimal hydrophobic interactions
during ligand binding, as the docking simulations predict AGP 18:1 to bind lower in the
pocket towards the hydrophobic core (Figure 16). The model at its current stage of
optimization predicts the polar carbonyl oxygen of LPA to bind 3.61Å from the non-polar
sidechain of L189 (L5.41) resulting in an entropically unfavorable interaction. The
position of the carbonyl oxygen would be more entropically unfavorable if LPA bound as
low in the pocket as AGP. Furthermore the geometry of the ester group in LPA is
trigonal planar with 120 degree bond angles and the geometry of the ether group in AGP
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is tetrahedral with 109.5 degree bond angles. Thus the ether bond in AGP is rotatable
and can bind in a bend near the headgroup binding pocket compared to the rigid planar
ester bond in LPA, a polar functional group that cannot bind in a bend however can
participate in hydrogen bonding. The model predicts the carbonyl group of LPA does not
bind near a polar residue for a hydrogen bonding interaction, which could be the cause of
the higher EC50 value of LPA relative to AGP. The model predicts there is a bend near
the headgroup binding pocket (Figure 16) at which the rotatable ether bond in AGP and
carbon-carbon bond in OTP can better bind relative to the rigid planar bond in LPA. The
docked complexes predict the double bond in LPA, AGP, and OTP ligands to bind in
close proximity to M105 (Table 9, Figure 16). Also the model predicts the cis alkene at
carbon 9 is positioned 13.82Å from the phosphate group of LPA, 10.53Å from the
phosphate group of AGP, and 8.43Å from the thiophosphate group of OTP. Therefore
the distance is shorter between the bend in the pocket that accommodates the double bond
and the headgroup in compounds that lack the glycerol backbone. The sulfur atom in
OTP is larger in size than the oxygen atom in LPA or AGP and can better accommodate
negative charge. Also OTP is shorter in length relative to LPA and AGP because it lacks
the glycerol backbone. Therefore the cis double bond at carbon-9 positioned closer in
proximity to the thiophosphate headgroup is preferred relative to LPA for receptor
activation. However compound 39 consists of an 18:1 delta 11 chain length (Table 14)
relative to the 18:1 delta 9 chain length in OTP, which should increase the headgroupalkene distance to a distance analogous to LPA or AGP because the model predicts LPA
and AGP are not as extended as OTP in the bound complexes (Figure 16). Compound 39
had an EC50 value 3.9 fold higher than LPA (Table 14), 10.5 fold higher than AGP, and
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6.9 fold higher than OTP. This proves that for the 18:1 chain lengths, the cis-double
bond is preferred at the delta 9 position.
Discussion and Future Directions
The LPA analogs with doubly charged headgroups elicit EDG LPA receptor
activity (106, 107), similar to the finding that this feature is important for LPA5 receptor
activity. The EDG receptors in addition to LPA5 show reduced activity with shorter
chain lengths. Also in the context of LPA analogs, LPA3 has been shown to prefer
unsaturation at the cis delta-9 position (107). Within the LPA5 system, the assay of
compounds with thiophosphate headgroups proved the double bond is preferred closer to
the larger thiophoshate headgroup that better accommodates negative charge. Therefore
an extensive investigation of the region of the binding pocket that locks the cis double
bond relative to the headgroup is needed in future studies. This can be accomplished by
the selection of residues to mutate predicted to be in close proximity to the cis-alkene.
More specifically the homology model predicts the cis-alkene of OTP to bind within
4.5Å from the hydrophobic residues F71, M105, A286 and the polar residues Ser108 and
Cys109 (Figure 21). The cis-alkene is predicted to bind above Ser108 and Cys109, and
perhaps the cis geometry of the double bond reduces unfavorable interaction with the
polar residues more than the trans geometry. Mutation of these polar residues to a
hydrophobic alanine residue is predicted to increase potency OTP because of the added
hydrophobic interactions with the tail resulting in a more hydrophobic environment that
binds the alkene. However in compound 39 the cis double bond is farther from the
thiophosphate headgroup at the carbon 11 position, which contributes to the higher EC50
value of compound 39 (Table 14).
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R261
H160
R276
R78
F101

F71
M105
A286

S108
C109

Figure 21. OTP 18:1 and LPA5 Model Complex. OTP 18:1 is shown in ball and
sticks. Hydrophobic residues involved in ligand recognition are colored yellow.
Additional residues to mutate to investigate environment of the cis-alkene are colored
purple.

The modeling in combination with the SAR data suggests that ligands with
multiply charged headgroups are better activators of LPA5. Based on the integrated
modeling, mutagenesis, and SAR data presented in chapter 3 and 4, a candidate LPA5
agonist is an 18:1 OTP analog with a pyrothiophosphate headgroup that has a negative
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three charge at neutral pH, and a cis double bond at a position analogus to the cis-delta 9
from the terminal thiophosphate, shown in Figure 22. Also, the amide functional group
has been shown to enhance receptor activity, relative to the hydrocarbon attachment
directly to the headgroup, therefore the candidate agonist includes an amide functional
group. Because the thiophosphate group pairs best with the bend induced by alkenes at
the delta nine position and because the added charge should stabilize the cationic binding
pocket, this candidate agonist is predicted to be more potent than OTP. FPP has a
pyrophosphate headgroup and is a full LPA5 agonist (104, 64), however is less potent
than OTP because the double bonds within FPP are located closer to the headgroup
(Table 8), and are trans rather than cis. The phosphate analog of OTP did not saturate
(compound 32, Table 15) which proved the thiophosphate group in the absence of
glycerol is spaced more optimally from the bend induced by the cis-alkene at the carbon
9 position for 18:1 chain lengths. However for 17:1 chain lengths with the cis-alkene at
the carbon 10 position, the phosphate headgroup (compound 31, Table 15) showed better
activity compared to the thiophosphate analog (compound 29, Table 15); and yet the
phosphate analog was less potent than LPA (Table 15). Therefore the 18:1 chain length
with the thiophosphate headgroup and cis delta 9 is the preferred chain length and double
bond geometry for optimal activity. The data presented in this dissertation confirms an
alkyl-LPA preference in LPA5 (EC50 value of 25nM) relative to acyl-LPA (EC50 value of
150nM) as previously observed by Khandoga, et al, in their investigation of the relative
effects of LPA and AGP on platelet and megakaryoctye shape change (59, 60).
Furthermore the data shows OTP a more potent activator of LPA5 relative to LPA. The
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pyrothiophosphate group is synthetically feasible (108, 109) and the suggested LPA5
agonist is predicted to be more potent than OTP.

Figure 22. Candidate LPA5 agonist.

The molecular dynamics results presented in Table 12 predict ligand binding and
the experimental mutagenesis results presented in Table 13 are a measure of receptor
activation. Binding can occur without receptor activation, however receptor activation
cannot occur without binding. Molecular dynamics relaxed the original estimate of the
complex geometry allowing for an estimation of induced fit and suggest R78, R261, and
R276 all contribute to ligand binding, however, the experimental mutagenesis results
proved only R78 and R276 were essential for receptor activation (Table 13). Therefore
mutant models of R78, R261, and R276 are needed in future studies as well as
radioligand binding assays to investigate whether the absence of receptor activation is
due to a lack of ligand binding, or due to a role of particular residues in stabilizing the
active conformation of the receptor.
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